# EDGAR Filing Document

**Accession Number:** 0001778129
**File Stem:** 0000950170-25-104975
**Filing Date:** 2025-8
**Character Count:** 170411
**Document Hash:** 1e5dbe3fe179afceb237ea083d10b2ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-104975.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0000950170-25-104975

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 121

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TerrAscend Corp.
- **CENTRAL INDEX KEY:** 0001778129
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56363
- **FILM NUMBER:** 251193859

**BUSINESS ADDRESS:**
- **STREET 1:** 3610 MAVIS ROAD
- **CITY:** MISSISSAUGA
- **STATE:** A6
- **ZIP:** L5B 4A7
- **BUSINESS PHONE:** 855 837-7295

**MAIL ADDRESS:**
- **STREET 1:** 3610 MAVIS ROAD
- **CITY:** MISSISSAUGA
- **STATE:** A6
- **ZIP:** L5B 4A7

?xml version='1.0' encoding='ASCII'? 10-Q

ROC

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM** 10-Q

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended** **June 30,** 2025

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission File Number:** 021-340690

------

TERRASCEND CORP.

**(Exact Name of Registrant as Specified in its Charter)**

------

---

| | |
|:---|:---|
| Ontario | N/A |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| 77 City Centre Drive<br>Suite 501 - East Tower<br>Mississauga**,** Ontario**,** Canada | L5B 1M5 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (**844**)** 628-3100

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☒ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 6, 2025, the registrant had 306,233,661 common shares, no par value, outstanding.

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| **PART I.** | [<u>FINANCIAL INFORMATION</u>](#part_i_financial_information) | 1 |
| Item 1. | [<u>Financial Statements (Unaudited)</u>](#item_1_financial_statements) | 1 |
|  | [<u>Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024</u>](#balance_sheets) | 1 |
|  | [<u>Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024</u>](#consolidated_stmts_ops_comprehensiv_loss) | 2 |
|  | [<u>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity for the three and six months ended June 30, 2025 and 2024</u>](#shareholder_equity_) | 3 |
|  | [<u>Unaudited Interim Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024</u>](#consolidated_statements_cash_flows) | 5 |
|  | [<u>Notes to Unaudited Interim Condensed Consolidated Financial Statements</u>](#notes) | 7 |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | 27 |
| Item 3. | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3_qnq) | 39 |
| Item 4. | [<u>Controls and Procedures</u>](#item_4controlsandprocedures) | 39 |
| **PART II.** | [<u>OTHER INFORMATION</u>](#part_ii) | 40 |
| Item 1. | <u>Legal Proceedings</u> | 40 |
| Item 1A. | [<u>Risk Factors</u>](#item_1ariskfactors) | 40 |
| Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item2_unrregsales) | 40 |
| Item 3. | [<u>Defaults Upon Senior Securities</u>](#item3) | 41 |
| Item 4. | [<u>Mine Safety Disclosures</u>](#item4) | 41 |
| Item 5. | [<u>Other Information</u>](#item_5_market_registrants) | 41 |
| Item 6. | [<u>Exhibits</u>](#exhibits) | 43 |
| [<u>Signatures</u>](#signatures) | [<u>Signatures</u>](#signatures) | 44 |

---

------

**Cautionary Note Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains statements that TerrAscend Corp. (the "Issuer") believes are, or may be considered to be, "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q regarding the prospects of the industry in which the Issuer, its subsidiaries, TerrAscend Growth Corp. ("TerrAscend") and its subsidiaries (collectively, the "Company") operate or the Company's prospects, plans, financial position or business strategy may constitute forward-looking statements. Such statements can be identified by the use of forward-looking terminology such as "can", "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements with respect to:

• the projected performance of the Company's business and operations;

• the Company's estimates and expectations regarding revenues, expenses and need for substantial additional financing, and its ability to obtain additional financing;

• the Company's ability to source investment opportunities and complete future acquisitions, including in respect of entities in the United States, the ability to finance such acquisitions or operations in the United States, and the expected impact thereof, including potential issuances of common shares in the capital of the Company;

• the Company's ability to market itself to the capital markets, including its ability to raise equity as a result of its corporate ownership structure;

• expectations with respect to future production costs;

• the expected impact of taxation on the Company's profitability and the uncertainty around timing of any legislative changes impacting unfavorable tax treatment;

• the expected growth in the number of the Company's dispensaries and the jurisdictions in which the Company operates;

• the competitive conditions of the industry in which the Company operates;

• the impact of the Company's exit from the Michigan market on its operations and financial results;

• federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States;

• the legalization of the regulated use of cannabis for medical and/or adult-use in the United States and the related timing and impact thereof;

• laws and regulations and any amendments thereto applicable to the business and the impact thereof;

• the possibility of actions by individuals, or U.S. federal government enforcement actions, against the Company and the potential impact of such actions on the Company;

• the competitive advantages and business strategies of the Company;

• the grant, renewal and impact of any license or supplemental license to conduct activities with or without cannabis or any amendments thereof;

• the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis;

• the Company's ability to source and operate facilities in the United States;

• the Company's ability to integrate and operate the assets it acquires or may acquire in the future;

• expectations regarding the Company's liquidity;

• expectations regarding the Company's Share Repurchase Program (as defined below); and

• other risks and uncertainties, including those referenced the section titled "*Risk Factors*" in this Quarterly Report.

Certain of the forward-looking statements contained herein concerning the cannabis industry and the general expectations of the Company concerning the cannabis industry are based on estimates prepared by the Company using data from publicly-available

------

governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the cannabis industry. Such data is inherently imprecise. The cannabis industry involves risks and uncertainties that are subject to change based on various factors, which factors are described further below.

With respect to the forward-looking statements contained in this Quarterly Report on Form 10-Q, the Company has made assumptions regarding, among other things: (i) its ability to generate cash flows from operations and obtain necessary financing on acceptable terms; (ii) general economic, financial market, regulatory and political conditions in jurisdictions in which the Company operates; (iii) the output from the Company's operations; (iv) consumer interest in the Company's products; (v) competition in the cannabis industry; (vi) anticipated and unanticipated costs; (vii) government regulation of the Company's activities and products; (viii) government regulation of licensing, taxation and environmental protection; (ix) the timely receipt of any required regulatory approvals; (x) the Company's ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; (xi) the Company's ability to conduct operations in a safe, efficient and effective manner; and (xii) the Company's construction plans and timeframe for completion of such plans.

Readers are cautioned that the above list of cautionary statements is not exhaustive. Known and unknown risks, many of which are beyond the control of the Company, could cause actual results to differ materially from the forward-looking statements in this Quarterly Report on Form 10-Q. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and those discussed under Item 1A – "*Risk Factors*" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 6, 2025. The purpose of forward-looking statements is to provide the reader with a description of management's expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance on forward-looking statements contained in this Quarterly Report on Form 10-Q. The Company can give no assurance that such expectations will prove to have been correct. Forward-looking statements contained herein are made as of the date of this Quarterly Report on Form 10-Q and are based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking statements are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by applicable law.

------

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Balance Sheets** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **At** | **At** |
|  | **June 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $26672 | $26381 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 110 | 606 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 19989 | 20224 |
| &nbsp;&nbsp;&nbsp;Investments | 992 | 1727 |
| &nbsp;&nbsp;&nbsp;Inventory | 35409 | 39672 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 4972 | 5123 |
| &nbsp;&nbsp;&nbsp;Assets from discontinued operations, current | 44939 | 83155 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 133083 | 176888 |
| **Non-current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 126298 | 124165 |
| &nbsp;&nbsp;&nbsp;Deposits | 168 | 168 |
| &nbsp;&nbsp;&nbsp;Operating lease right of use assets | 28890 | 28755 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 173291 | 169604 |
| &nbsp;&nbsp;&nbsp;Goodwill | 109770 | 106929 |
| &nbsp;&nbsp;&nbsp;Other non-current assets | 507 | 722 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total non-current assets | 438924 | 430343 |
| **Total assets** | $**572007** | $**607231** |
| **Liabilities and shareholders' equity** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $37008 | $40349 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 4080 | 3575 |
| &nbsp;&nbsp;&nbsp;Convertible debt | 10221 |  |
| &nbsp;&nbsp;&nbsp;Loans payable | 554 | 6761 |
| &nbsp;&nbsp;&nbsp;Contingent consideration payable | 1672 | 3121 |
| &nbsp;&nbsp;&nbsp;Operating lease liability | 1265 | 1322 |
| &nbsp;&nbsp;&nbsp;Derivative liability | 178 | 92 |
| &nbsp;&nbsp;&nbsp;Corporate income tax payable | 12694 | 11531 |
| &nbsp;&nbsp;&nbsp;Liabilities from discontinued operations | 23991 | 24298 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 91663 | 91049 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Loans payable | 199119 | 183461 |
| &nbsp;&nbsp;&nbsp;Operating lease liability | 31036 | 30664 |
| &nbsp;&nbsp;&nbsp;Derivative liability |  | 451 |
| &nbsp;&nbsp;&nbsp;Convertible debt |  | 9114 |
| &nbsp;&nbsp;&nbsp;Deferred income tax liability | 9025 | 8428 |
| &nbsp;&nbsp;&nbsp;Contingent consideration payable |  | 172 |
| &nbsp;&nbsp;&nbsp;Liability on uncertain tax position | 122692 | 106991 |
| &nbsp;&nbsp;&nbsp;Other long term liabilities | 85 | 85 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total non-current liabilities | 361957 | 339366 |
| **Total liabilities** | 453620 | 430415 |
| Commitments and contingencies |  |  |
| **Shareholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;Share capital |  |  |
| &nbsp;&nbsp;&nbsp;Series A, convertible preferred stock, no par value, unlimited shares authorized; 10,850 and 12,350 shares outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Series B, convertible preferred stock, no par value, unlimited shares authorized; 600 and 600 shares outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Exchangeable shares, no par value, unlimited shares authorized; 63,492,038 and 63,492,038 shares outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Common shares, no par value, unlimited shares authorized; 306,117,417 and 293,232,131 shares outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Treasury stock, no par value; nil and 129,500 shares outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Additional paid in capital | 957238 | 952463 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 2171 | 3011 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (841470) | (778514) |
| &nbsp;&nbsp;&nbsp;Non-controlling interest | 448 | (144) |
| **Total shareholders' equity** | 118387 | 176816 |
| **Total liabilities and shareholders' equity** | $**572007** | $**607231** |

---

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

------

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| **Revenue, net** | $**65006** | $**67196** | $**129309** | $**136471** |
| **Cost of sales** | **31771** | **33837** | **61393** | **68942** |
| **Gross profit** | **33235** | **33359** | **67916** | **67529** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;General and administrative | 20980 | 22632 | 42129 | 43709 |
| &nbsp;&nbsp;Amortization and depreciation | 1284 | 1258 | 2573 | 2553 |
| &nbsp;&nbsp;Impairment of property and equipment and right of use assets |  |  |  | 2438 |
| &nbsp;&nbsp;Other operating income |  | (1169) |  | (1169) |
| **Total operating expenses** | **22264** | **22721** | **44702** | **47531** |
| **Income from operations** | **10971** | **10638** | **23214** | **19998** |
| **Other expense (income)** |  |  |  |  |
| &nbsp;&nbsp;Finance and other expenses | 8747 | 8561 | 17082 | 16803 |
| &nbsp;&nbsp;Unrealized and realized (gain) loss on investments | (7) | 227 | 735 | 227 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss from revaluation of contingent consideration | (34) | 1827 | 346 | 3220 |
| &nbsp;&nbsp;Gain on fair value of derivative liabilities | (279) | (2922) | (376) | (1939) |
| &nbsp;&nbsp;Unrealized and realized foreign exchange (gain) loss | (648) | 104 | (607) | 389 |
| **Income from continuing operations before provision for income taxes** | **3192** | **2841** | **6034** | **1298** |
| &nbsp;&nbsp;Provision for income taxes | 9598 | 9126 | 20105 | 16779 |
| **Net loss from continuing operations** | $**(6406)** | $**(6285)** | $**(14071)** | $**(15481)** |
| **Discontinued operations:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations, net of tax | $(41701) | $48 | $(46305) | $(5607) |
| **Net loss** | $**(48107)** | $**(6237)** | $**(60376)** | $**(21088)** |
| Foreign currency translation adjustment | 854 | (260) | 840 | (658) |
| **Comprehensive loss** | $**(48961)** | $**(5977)** | $**(61216)** | $**(20430)** |
| **Net loss from continuing operations attributable to:** |  |  |  |  |
| &nbsp;&nbsp;Common and proportionate Shareholders of the Company | $(7684) | $(8228) | $(16651) | $(19628) |
| &nbsp;&nbsp;Non-controlling interests | $1278 | $1943 | $2580 | $4147 |
| **Comprehensive loss attributable to:** |  |  |  |  |
| &nbsp;&nbsp;Common and proportionate Shareholders of the Company | $(50239) | $(7920) | $(63796) | $(24577) |
| &nbsp;&nbsp;Non-controlling interests | $1278 | $1943 | $2580 | $4147 |
| Net loss per share - basic & diluted: |  |  |  |  |
| &nbsp;&nbsp;Continuing operations | $(0.03) | $(0.03) | $(0.06) | $(0.07) |
| &nbsp;&nbsp;Discontinued operations | (0.14) |  | (0.16) | (0.02) |
| Net loss per share - basic & diluted | $(0.17) | $(0.03) | $(0.22) | $(0.09) |
| Weighted average number of outstanding common shares - basic & diluted | 299087022 | 291488661 | 296137440 | 291053614 |

---

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

------

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity**

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)* 

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Number of Shares** | **Number of Shares** | **Number of Shares** | **Number of Shares** | **Number of Shares** |  |  |  |  |  |
|  |  |  | **Convertible Preferred Stock** | **Convertible Preferred Stock** |  |  |  |  |  |  |
|  | **Common Shares** | **Exchangeable Shares** | **Series A** | **Series B** | **Common Shares Equivalent** | **Additional paid in capital** | **Accumulated other comprehensive loss** | **Accumulated deficit** | **Non-controlling interest** | **Total** |
| **Balance at December 31, 2023** | **288327497** | **63492038** | **12350** | **600** | **364769739** | $**944859** | $**1799** | **(704162)** | **(1756)** | $**240740** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - stock options, warrant and RSU exercises** | 69229 |  |  |  | 69229 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Share-based compensation expense** |  |  |  |  |  | 1485 |  |  |  | **1485** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Options and warrants expired/forfeited** |  |  |  |  |  | (3819) |  | 3819 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Capital distributions** |  |  |  |  |  |  |  |  | (337) | **(337)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Acquisition of non-controlling interest** | 2888088 |  |  |  | 2888088 | 3300 |  |  | 1374 | **4674** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net (loss) income for the period** |  |  |  |  |  |  |  | (17055) | 2204 | **(14851)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Foreign currency translation adjustment** |  |  |  |  |  |  | 398 |  |  | **398** |
| **Balance at March 31, 2024** | **291284814** | **63492038** | **12350** | **600** | **367727056** | $**945825** | $**2197** | $**(717398)** | $**1485** | $**232109** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - stock options, warrant and RSU exercises** | 222616 |  |  |  | 222616 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Share-based compensation expense** |  |  |  |  |  | 1960 |  |  |  | 1960 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Options and warrants expired/forfeited** |  |  |  |  |  | (1988) |  | 1988 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Capital distributions** |  |  |  |  |  |  |  |  | (1946) | (1946) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss for the period** |  |  |  |  |  |  |  | (8180) | 1943 | (6237) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Foreign currency translation adjustment** |  |  |  |  |  |  | 260 |  |  | 260 |
| **Balance at June 30, 2024** | **291507430** | **63492038** | **12350** | **600** | **367949672** | $**945797** | $**2457** | $**(723590)** | $**1482** | $**226146** |

---

------

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Continued)**

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)* 

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Number of Shares** | **Number of Shares** | **Number of Shares** | **Number of Shares** | **Number of Shares** |  |  |  |  |  |  |
|  |  |  | **Convertible Preferred Stock** | **Convertible Preferred Stock** |  |  |  |  |  |  |  |
|  | **Common Shares** | **Exchangeable Shares** | **Series A** | **Series B** | **Common Shares Equivalent** | **Treasury Stock** | **Additional paid in capital** | **Accumulated other comprehensive loss** | **Accumulated deficit** | **Non-controlling interest** | **Total** |
| **Balance at December 31, 2024** | **293232131** | **63492038** | **12350** | **600** | **369674373** | **(129500)** | $**952463** | $**3011** | $**(778514)** | $**(144)** | $**176816** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - stock options, warrant and RSU exercises** | 54350 |  |  |  | 54350 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Share-based compensation expense** |  |  |  |  |  |  | 1514 |  |  |  | 1514 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Capital distributions** |  |  |  |  |  |  |  |  |  | (738) | (738) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Repurchase of common stock, including excise tax** | (637000) |  |  |  | (637000) | 129500 | (231) |  |  |  | (231) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net (loss) income for the period** |  |  |  |  |  |  |  |  | (13571) | 1302 | (12269) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Foreign currency translation adjustment** |  |  |  |  |  |  |  | 14 |  |  | 14 |
| **Balance at March 31, 2025** | **292649481** | **63492038** | **12350** | **600** | **369091723** | **—** | $**953746** | $**3025** | $**(792085)** | $**420** | $**165106** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - stock options, warrant and RSU exercises** | 354950 |  |  |  | 354950 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - acquisitions** | 4570637 |  |  |  | 4570637 |  | 1278 |  |  |  | 1278 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - conversion** | 1500000 |  | (1500) |  | 1500000 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Shares issued - price protection adjustment** | 7577349 |  |  |  | 7577349 |  | 1581 |  |  |  | 1581 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Repurchase of common stock, including excise tax** | (535000) |  |  |  | (535000) |  | (146) |  |  |  | (146) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Share-based compensation expense** |  |  |  |  |  |  | 779 |  |  |  | 779 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Capital distributions** |  |  |  |  |  |  |  |  |  | (1250) | (1250) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss for the period** |  |  |  |  |  |  |  |  | (49385) | 1278 | (48107) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Foreign currency translation adjustment** |  |  |  |  |  |  |  | (854) |  |  | (854) |
| **Balance at June 30, 2025** | **306117417** | **63492038** | **10850** | **600** | **382559659** | **—** | $**957238** | $**2171** | $**(841470)** | $**448** | $**118387** |

---

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

------

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Statements of Cash Flows**

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| **Operating activities** |  |  |
| &nbsp;&nbsp;Net loss from continuing operations | $(14071) | $(15481) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion expense | 4306 | 7862 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation of property and equipment and amortization of intangible assets | 7729 | 7576 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of operating right-of-use assets | 805 | 777 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 2293 | 3445 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax expense (recovery) | 597 | (415) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on fair value of derivative liabilities | (376) | (1939) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized and realized loss on investments | 735 | 227 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from revaluation of contingent consideration | 346 | 3220 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for expected credit loss | 673 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized and realized foreign exchange (gain) loss | (607) | 389 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment and other | (5) | 1269 |
| &nbsp;&nbsp;Changes in operating assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables | (511) | 1517 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 4580 | 1400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | (5046) | (4289) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid and tax related liabilities | 16862 | 25238 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expense and other current assets | 79 | (52) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | 90 | 2572 |
| **Net cash provided by operating activities - continuing operations** | 18479 | 33316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities - discontinued operations | (7658) | (7177) |
| **Net cash provided by operating activities** | 10821 | 26139 |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in property and equipment | (4650) | (4094) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest received on investment in note receivable | 123 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in intangible assets | (726) | (699) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash portion of consideration paid in acquisitions, net of cash acquired | (5128) | (250) |
| **Net cash used in investing activities - continuing operations** | (10381) | (5043) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by investing activities - discontinued operations | (737) | 200 |
| **Net cash used in investing activities** | (11118) | (4843) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from loan payable, net of transaction costs | 5000 | 3137 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loan principal paid | (1966) | (16306) |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital distributions paid to non-controlling interests | (1988) | (1564) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment for contingent consideration | (386) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments made for financing obligations and finance lease |  | (271) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of common shares | (377) |  |
| **Net cash provided by (used in) financing activities- continuing operations** | 283 | (15004) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities- discontinued operations |  | (1538) |
| **Net cash provided by (used in) financing activities** | 283 | (16542) |
| **Net (decrease) increase in cash and cash equivalents and restricted cash during the period** | (14) | 4754 |
| Net effects of foreign exchange | (191) | 390 |
| **Cash and cash equivalents and restricted cash, beginning of the period** | 26987 | 25347 |
| **Cash and cash equivalents and restricted cash, end of the period** | $26782 | $30491 |

---

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

------

TerrAscend Corp.

**Unaudited Interim Condensed Consolidated Statements of Cash Flows (Continued)**

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| **Supplemental disclosure with respect to cash flows** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid (received) for income tax, net | $4573 | $(8116) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest paid | 13266 | 12599 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease termination fee paid |  | 271 |
| **Non-cash transactions** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity and warrant liability issued for acquisitions and non-controlling interest | $— | $4674 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distribution payable to non-controlling interests |  | 719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in accrued capital expenditures | 2115 | 811 |

---

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

**1. Nature of operations**

TerrAscend Corp. (the "Issuer") was incorporated under the Business Corporations Act (Ontario) on March 7, 2017. The Issuer, through its subsidiaries, TerrAscend Growth Corp. ("TerrAscend") and its subsidiaries (collectively, "the Company"), is a leading North American cannabis company. TerrAscend has vertically integrated licensed operations in Pennsylvania, New Jersey, Michigan, Maryland and California and a retail operation in Ohio. In addition, the Company has retail operations in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada. In the United States, TerrAscend's cultivation and manufacturing provide product selection to both the medical and legal adult-use markets. Notwithstanding the fact that various states in the United States have implemented medical marijuana laws or have otherwise legalized the use of cannabis, the use of cannabis remains illegal under U.S. federal law for any purpose, by way of the Controlled Substances Act of 1970.

The Company operates under one reportable segment, which is the cultivation, production and sale of cannabis products.

The Company owns a portfolio of operating businesses, including:

• TerrAscend New Jersey ("TerrAscend NJ"), a majority owned operation with three dispensaries, and a cultivation/processing facility;

• TerrAscend Maryland ("TerrAscend MD"), a wholly-owned operation with four dispensaries, and a cultivation/processing facility;

• TerrAscend Pennsylvania ("TerrAscend PA"), a wholly-owned operation with six dispensaries, and a cultivation/processing facility;

• TerrAscend California ("TerrAscend CA"), a wholly-owned operation with four dispensaries, and a cultivation facility;

• TerrAscend Ohio ("TerrAscend OH"), a wholly-owned operation with one dispensary; and

• TerrAscend Canada Inc. ("TerrAscend Canada"), a cannabis retailer in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada ("Cookies Canada"); and

• TerrAscend Michigan ("TerrAscend MI"), a wholly-owned operation with twenty dispensaries, one cultivation facility, one processing facility, and two cultivation/processing facilities which were classified as discontinued operations during the six months ended June 30, 2025. See Note 7 for additional information.

The common shares in the capital of the Company ("Common Shares") commenced trading on the Canadian Securities Exchange ("CSE") on May 3, 2017 under the ticker symbol "TER" and continued trading on the CSE until the listing of the Common Shares on the Toronto Stock Exchange (the "TSX"). Effective July 4, 2023, the Common Shares commenced trading on the TSX under the ticker symbol "TSND". The Common Shares commenced trading on OTCQX on October 22, 2018 under the ticker symbol "TRSSF", which was subsequently changed to "TSNDF", effective July 6, 2023. The Company's registered office is located at 77 City Centre Drive, Suite 501, Mississauga, Ontario, L5B 1M5, Canada.

**2.** **Summary of significant accounting policies**

(a)Basis of presentation

These unaudited interim condensed consolidated financial statements included herein (the "Consolidated Financial Statements") of the Company and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

The accompanying Consolidated Financial Statements contained in this report are unaudited. In the opinion of management, these Consolidated Financial Statements have been prepared on the same basis as the annual consolidated financial statements and notes thereto of the Company and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of the Company's financial position and operating results. The results for the three and six months ended June 30, 2025 are not necessarily indicative of the operating results for the year ended December 31, 2025, or any other interim or future periods.

The accompanying Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto of the Company for the year ended December 31, 2024 contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (the "SEC") on March 6, 2025

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

(the "Annual Report"). There were no significant changes to the policies disclosed in Note 2 of the summary of significant accounting policies of the Company's audited consolidated financial statements for the year ended December 31, 2024 in the Company's Annual Report.

(b) Discontinued operations and assets held for sale

During the three months ended June 30, 2025, the Company committed to a plan to exit the Michigan market. The Company is currently engaged in an active program to sell the assets of the Michigan business which is expected to be substantially completed in the second half of 2025.

The Company evaluated whether its plan to exit the Michigan market qualifies as discontinued operations in accordance with Accounting Standards Codification ("ASC") 205-20, *Discontinued Operations*. A disposal of a component or a group of components is reported in discontinued operations if the disposal represents a strategic shift that has or will have a major effect on the Company's operations and financial results when the following occurs: (i) a component (or group of components) meets the criteria to be classified as held for sale; (ii) the component or group of components is disposed of by sale; or (iii) the component or group of components is disposed of other than by sale (for example, by abandonment or in a distribution to owners in a spin-off).

The Company determined that its plan to exit the Michigan market is considered a strategic shift that will have a major effect on the Company's operations and financial results and met the criteria for classification as discontinued operations. As a result, the assets and liabilities of TerrAscend MI are presented as held for sale in accordance with ASC 360-10, *Impairment or Disposal of Long Lived Assets* ("ASC 360-10") in the unaudited interim condensed consolidated balance sheets ("Consolidated Balance Sheets"), the operating results are presented as discontinued operations in the unaudited interim condensed consolidated statements of operations ("Consolidated Statements of Operations and Comprehensive Loss"), and net cash used is presented as discontinued operations in the statements of cash flows. The Company's assets to be disposed of and for which there is a committed plan of disposal are classified as assets held for sale and at the lower of carrying value or fair value, less costs to sell.

Prior period amounts have been retrospectively adjusted to conform to the current period presentation. Certain prior period amounts, primarily related to discontinued operations, have been reclassified in the Consolidated Financial Statements and accompanying notes to conform to the current period presentation. Unless otherwise noted, amounts and disclosures throughout these notes to the Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 7 for additional information.

**3.** **Consolidation**

The Company consolidates entities in which it has a controlling financial interest by evaluating whether the entity is a voting interest entity ("VOE") or a variable interest entity ("VIE").

In connection with the listing of its Common Shares on the TSX, the Company undertook a strategic reorganization of its ownership structure (the "2023 Reorganization") to align with TSX regulatory requirements regarding U.S. based operations, in accordance with the TSX's Staff Notice 2017-0009. Specifically, the 2023 Reorganization was designed to separate the Company's Canadian retail operations from its U.S. cultivation and manufacturing businesses in a manner that supports compliance with applicable listing standards while preserving the Company's ability to consolidate the financial results of its U.S. operations under U.S. GAAP. Following the completion of the 2023 Reorganization, the Company holds a 95% equity interest in its Canadian retail business and maintains a variable interest in its U.S. operations, which are consolidated through a VIE model. The Company continues to consolidate both operations under two distinct consolidation models in accordance with ASC 810, *Consolidation* ("ASC 810").

Subsequent to the 2023 Reorganization, all operations in the United States have a functional currency of the U.S. dollar ("USD"). Canadian operations continue to have a functional currency of the Canadian dollar ("CAD").

<u>Voting Interest Entities</u>

A VOE is an entity in which (1) the total equity investment at risk is deemed sufficient to absorb the expected losses of the entity, (2) the at-risk equity holders, as a group, have all of the characteristics of a controlling financial interest and (3) the entity is structured with substantive voting rights. The Company consolidates the Canadian operations under a VOE model based on the controlling financial interest obtained through Common Shares with substantive voting rights.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

The Company's Canadian retail operations are conducted through a subsidiary that is 95% owned by TerrAscend Canada, a wholly owned subsidiary of the Issuer. These operations are consolidated under the VOE model based on the controlling financial interest obtained through Common Shares with substantive voting rights. The remaining Canadian subsidiaries are either wholly owned or majority owned, and are not currently engaged in active operations.

<u>Variable Interest Entities</u>

A VIE is an entity that lacks one or more characteristics of a controlling financial interest defined under the voting interest model. The Company consolidates VIE when it has a variable interest that provide it with (1) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits).

In connection with the 2023 Reorganization, TerrAscend issued and sold, on a private placement basis, Class A shares in the capital of TerrAscend ("Class A Shares") for aggregate gross proceeds of $1,000 to an investor ("Investment"). See Note 10 for accounting treatment of the Class A Shares. Following the closing of the Investment, the Class B shares ("Class B Shares") in the capital of TerrAscend held by the Company, representing all of the issued and outstanding Class B shares, were automatically exchanged for non-voting, non-participating exchangeable shares in the capital of TerrAscend ("Non-Voting Shares"), representing approximately 99.8% of the issued and outstanding shares of TerrAscend on an as-converted basis. As a result of the limited rights associated with Non-Voting Shares that the Company holds following the closing of the Investment, the Company and TerrAscend entered into a protection agreement dated April 18, 2023 ("Protection Agreement"). The Protection Agreement provides for certain negative covenants in order to preserve the value of the Non-Voting Shares until such time as the Non-Voting Shares are converted into Class A Shares.

The Issuer determined that TerrAscend is a VIE, as all of the Company's U.S. activities continue to be conducted on behalf of the Company which has disproportionately few voting rights. After conducting an analysis of the following VIE factors; purpose and design of the VIE, the Protection Agreement in place, the structure of the Company's board of directors (the "Board"), and substantive kick-out rights of the holders of the Class A Shares, it was determined that the Company has the power to direct the activities of TerrAscend. In addition, given the structure of the Class A Shares where all of the losses and substantially all of the benefits of TerrAscend are absorbed by the Company, the Company consolidates as the primary beneficiary in accordance with ASC 810. Although the Company does not currently hold Class A Shares, the Non-Voting Shares are exchangeable at the Company's discretion and represent substantially all of the economic interest in the VIE. The investor's Class A Shares provide only a fixed annual return and do not participate in the residual economics of the VIE, in accordance with the Protection Agreement, which supports the Company's conclusion that it is the primary beneficiary of TerrAscend.

The Company's U.S. operations are consolidated through the VIE model. Therefore, substantially all of the Company's current assets, non-current assets, current liabilities and non-current liabilities are consolidated through the VIE model.

**4.** **Accounts receivable, net**

The Company's accounts receivable, net consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Trade receivables | $19383 | $19002 |
| Sales tax receivable | 1228 | 970 |
| Other receivables | 330 | 563 |
| Provision for current expected credit losses | (952) | (311) |
| **Total receivables, net** | $**19989** | $**20224** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Trade receivables | $19383 | $19002 |
| Less: provision for current expected credit losses | (952) | (311) |
| **Total trade receivables, net** | $**18431** | $**18691** |
| Of which |  |  |
| &nbsp;&nbsp;Current | 13046 | 11211 |
| &nbsp;&nbsp;31-90 days | 3053 | 3998 |
| &nbsp;&nbsp;Over 90 days | 3284 | 3793 |
| &nbsp;&nbsp;Less: current expected credit losses | (952) | (311) |
| **Total trade receivables, net** | $**18431** | $**18691** |

---

**5.** **Acquisitions**

<u>Ratio Cannabis</u>

On May 6, 2025 ("Ratio Acquisition Date"), the Company completed the acquisition of certain assets of Ratio Cannabis, LLC, a licensed cannabis operator, to expand its operational footprint. The total fair value consideration transferred in connection with the acquisition was $10,103. The fair value consideration was comprised of: (i) $5,261 in cash, (ii) a $3,564 secured promissory note bearing interest at a rate of 6.00% and maturing on May 6, 2027, and (iii) 4,570,637 Common Shares (the Ratio Share Consideration") valued at $1,278 using the trading price of the Common Shares on the acquisition date less an applicable share restriction discount of 30%.

The Ratio Share Consideration was subject to a statutory hold period restriction of six months, and therefore, a share restriction discount was considered in determining the fair value of the Ratio Share Consideration on the date of issuance, using an option pricing model.

The following table represents the fair value of assets acquired and liabilities assumed as of the May 6, 2025 acquisition date and allocation of the consideration to net assets acquired:

---

| | |
|:---|:---|
|  | **(In thousands)** |
| Cash and cash equivalents | $133 |
| Accounts receivable | 58 |
| Inventory | 317 |
| Prepaid expenses and other current assets | 54 |
| Intangible assets | 6700 |
| Goodwill | 2841 |
| **Net assets acquired** | $**10103** |
| Consideration paid in cash | $5261 |
| Promissory note payable | 3564 |
| Common shares of TerrAscend | 1278 |
| **Total consideration** | $**10103** |

---

The acquired intangible assets include a license, which is treated as a definite lived intangible asset and amortized over a 15-year period.

The consideration paid reflected the synergies, economies of scale, and workforce. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill recognized is expected to be deductible for income tax purposes.

The accounting for this acquisition has been provisionally determined at June 30, 2025. The fair value of net assets acquired, specifically with respect to intangible assets and goodwill have been determined provisionally and are subject to adjustment. Upon

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

completion of a comprehensive valuation and finalization of the purchase price allocation, the amounts above may be adjusted retrospectively to the acquisition date in future reporting periods.

Costs related to this transaction were $122, including legal, accounting, due diligence, and other transaction-related expenses and were recorded during the six months ended June 30, 2025.

On a standalone basis, had the Company acquired the business on January 1, 2025, sales estimates would have been $3,960 for the six months June 30, 2025 and net income estimates would have been $766. Actual sales and net income since the Ratio Acquisition Date are $1,242 and $253, respectively.

<u>Contingent consideration</u>

The balances of the Company's contingent considerations are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **State Flower** | **Apothecarium** | **Peninsula** | **Total** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Carrying amount, December 31, 2024** | $**787** | $**2120** | $**386** | $**3293** |
| Settlement of contingent consideration |  |  | (386) | (386) |
| Payments of contingent consideration | (442) | (1139) |  | (1581) |
| Loss on revaluation of contingent consideration | 93 | 253 |  | 346 |
| **Carrying amount, June 30, 2025** | $**438** | $**1234** | $**—** | $**1672** |
| **Less: current portion** | (438) | (1234) |  | (1672) |
| **Non-current contingent consideration** | $**—** | $**—** | $**—** | $**—** |

---

On June 2, 2025, the Company issued an additional 7,577,349 Common Shares related to the price protection clause from the previous acquisitions of State Flower and The Apothecarium businesses.

**6.** **Inventory** 

The Company's inventory of dry cannabis and cannabis derived products includes both purchased and internally produced inventory. The Company's inventory is comprised of the following items:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Raw materials | $520 | $400 |
| Finished goods | 15997 | 16182 |
| Work in process | 17296 | 21548 |
| Accessories, supplies and consumables | 1596 | 1542 |
| Total inventory | $35409 | $39672 |

---

**7.** **Discontinued operations**

During the six months ended June 30, 2025, the Company committed to a plan to exit the Michigan market. The Company received approval from the board of directors of TerrAscend Corp. (the "Board"), together with TerrAscend Corp.'s consolidated entities, and is currently engaged in an active program to sell the assets of TerrAscend MI, which is expected to be substantially completed in the second half of 2025. The Company determined that its decision to exit the Michigan market is considered a strategic shift that will have a major effect on the Company's operations and financial results and met the criteria for classification as discontinued operations.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

The following table summarizes the major classes of assets and liabilities of TerrAscend MI as of June 30, 2025 and December 31, 2024:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Current assets from discontinued operations** |  |  |
| &nbsp;&nbsp;Accounts receivable, net | 324 | 656 |
| &nbsp;&nbsp;Inventory | 8386 | 9128 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 992 | 917 |
| &nbsp;&nbsp;Property and equipment, net | $23290 | $59854 |
| &nbsp;&nbsp;Operating lease right of use assets | 11947 | 12600 |
| **Total current assets from discontinued operations** | $**44939** | $**83155** |
| **Current liabilities from discontinued operations** |  |  |
| &nbsp;&nbsp;Accounts payable and accrued liabilities | $6816 | $6376 |
| &nbsp;&nbsp;Deferred revenue | 1683 | 1554 |
| &nbsp;&nbsp;Operating lease liability | 12447 | 12994 |
| &nbsp;&nbsp;Finance lease liability | 1923 | 1864 |
| &nbsp;&nbsp;Other liabilities | 1122 | 1510 |
| **Total current liabilities from discontinued operations** | $**23991** | $**24298** |

---

The following table presents the results of operations of TerrAscend MI for the three and six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Revenue, net** | $**6190** | $**10327** | $**12883** | $**21685** |
| **Cost of Sales** | **4307** | **6003** | **8878** | **12800** |
| **Gross profit** | **1883** | **4324** | **4005** | **8885** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;General and administrative | 7089 | 1428 | 12320 | 8359 |
| &nbsp;&nbsp;Amortization and depreciation | 566 | 932 | 1040 | 1852 |
| &nbsp;&nbsp;Impairment of property and equipment | 34959 |  | 34959 |  |
| &nbsp;&nbsp;Other operating expense (income) | 57 | (17) | 57 | (17) |
| **Total operating expenses** | **42671** | **2343** | **48376** | **10194** |
| **Other expense (income)** |  |  |  |  |
| &nbsp;&nbsp;Finance and other expenses | 46 | 329 | 127 | 677 |
| **(Loss) income from discontinued operations before provision for income taxes** | **(40834)** | **1652** | **(44498)** | **(1986)** |
| &nbsp;&nbsp;Provision for income taxes | 867 | 1604 | 1807 | 3621 |
| **Net (loss) income from discontinued operations, net of tax** | $**(41701)** | $**48** | $**(46305)** | $**(5607)** |

---

ASC 360-10 requires a held-for-sale disposal group to be measured at the lower of its carrying amount and fair value less cost to sell. The Company adjusted the carrying amount of the assets in the disposal group within the scope of ASC 360-10 and recognized a total impairment loss of $34,959 on certain buildings, equipment, and leasehold improvements. The fair value of the disposal groups was primarily determined based on purchase offers from market participants subsequent to period end. An estimated cost to sell of 4% was

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

used in the valuations. The impairments were primarily attributable to the Company's expedited sales strategy, constructions in process that will no longer be complete, and the continued increase of competition in the Michigan market.

**8.** **Property and equipment**

Property and equipment consisted of:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Land | $3235 | $3235 |
| Assets in process | 2989 | 1956 |
| Buildings & improvements | 128956 | 123568 |
| Machinery & equipment | 24931 | 24662 |
| Office furniture & equipment | 4287 | 4282 |
| Total cost | 164398 | 157703 |
| Less: accumulated depreciation | (38100) | (33538) |
| Property and equipment, net | $126298 | $124165 |

---

Assets in process primarily represent construction in progress related to both cultivation and dispensary facilities not yet completed, or otherwise not placed in service.

Depreciation expense was $2,239 and $4,638 for the three and six months ended June 30, 2025, respectively, ($1,840 and $3,837 included in cost of sales) and $2,214 and $4,425 for the three and six months ended June 30, 2024, respectively, ($1,797 and $3,575 included in cost of sales).

**9.** **Intangible assets and goodwill**

Intangible assets consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| **At June 30, 2025** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| *Finite lived intangible assets* |  |  |  |
| &nbsp;&nbsp; Software | $2788 | $(1202) | $1586 |
| &nbsp;&nbsp; Licenses | 174164 | (27231) | 146933 |
| &nbsp;&nbsp; Non-compete agreements | 280 | (280) |  |
| Total finite lived intangible assets | 177232 | (28713) | 148519 |
| *Indefinite lived intangible assets* |  |  |  |
| &nbsp;&nbsp; Brand intangibles | 24772 |  | 24772 |
| Total indefinite lived intangible assets | 24772 |  | 24772 |
| **Intangible assets, net** | $**202004** | $**(28713)** | $**173291** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

---

| | | | |
|:---|:---|:---|:---|
| **At December 31, 2024** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| *Finite lived intangible assets* |  |  |  |
| &nbsp;&nbsp; Software | $2708 | $(964) | $1744 |
| &nbsp;&nbsp; Licenses | 167459 | (24371) | 143088 |
| &nbsp;&nbsp; Non-compete agreements | 280 | (280) |  |
| Total finite lived intangible assets | 170447 | (25615) | 144832 |
| *Indefinite lived intangible assets* |  |  |  |
| &nbsp;&nbsp; Brand intangibles | 24772 |  | 24772 |
| Total indefinite lived intangible assets | 24772 |  | 24772 |
| **Intangible assets, net** | $**195219** | $**(25615)** | $**169604** |

---

Amortization expense was $1,545 and $3,085 for the three and six months ended June 30, 2025, respectively, ($660 and $1,319 included in cost of sales) and $1,566 and $3,144 for the three and six months ended June 30, 2024, respectively, ($724 and $1,448 included in cost of sales).

Estimated future amortization expense for finite lived intangible assets for the next five years is as follows:

---

| | |
|:---|:---|
|  | **(In thousands)** |
| 2025 | $3377 |
| 2026 | 6594 |
| 2027 | 6515 |
| 2028 | 6464 |
| 2029 | 6350 |
| Thereafter | 119219 |
| Total | $148519 |

---

As of June 30, 2025, the weighted average amortization period remaining on intangible assets was 24.9 years.

The following table summarizes the activity in the Company's goodwill balance:

---

| | |
|:---|:---|
|  | **(In thousands)** |
| **Balance at December 31, 2024** | $106929 |
| Additions at acquisition date | 2841 |
| **Balance at June 30, 2025** | $109770 |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

**10.** **Loans payable** 

The Company's loans payable consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Pelorus term loan due October 2027 |  |  |
| &nbsp;&nbsp;Principal amount | $45478 | $45478 |
| &nbsp;&nbsp;Deferred financing cost | (933) | (1168) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net carrying amount | $44545 | $44310 |
| Maryland Acquisition loans (1) |  |  |
| &nbsp;&nbsp;Principal amount | $16373 | $18029 |
| &nbsp;&nbsp;Unamortized discount | (492) | (746) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net carrying amount | $15881 | $17283 |
| Ratio promissory note due May 2027 |  |  |
| &nbsp;&nbsp;Principal amount | $3980 | $— |
| &nbsp;&nbsp;Deferred financing cost | (384) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net carrying amount | $3596 | $— |
| FocusGrowth loan due August 2028 |  |  |
| &nbsp;&nbsp;Principal amount | $140000 | $140000 |
| &nbsp;&nbsp;Unamortized discount and deferred financing cost | (11510) | (12799) |
| &nbsp;&nbsp;Exit fee accretion | 933 | 390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net carrying amount | $129423 | $127591 |
| Other loans (2) | $6228 | $1038 |
| Total debt, net | $199673 | $190222 |
| Loans payable, current (2) | 554 | 6761 |
| Loans payable, non-current (2) | 199119 | 183461 |
| Total principal | $212059 | $204545 |

---

(1) For maturity breakout, refer to Maryland Acquisition Loans section below.

(2) Subsequent to June 30, 2025, the Company retired four of its debt facilities and modified an existing loan agreement. The modification of debt resulted in a reclassification of $19,440, net of deferred financing costs, between Loans payable, current and Loans payable, non-current. See Note 24 for further details of the refinancing.

Total interest paid on all loan payables was $6,846 and $13,266 for the three and six months ended June 30, 2025, respectively, and $6,335 and $12,599 for the three and six months ended June 30, 2024, respectively. The Company had accrued interest on loans payable of $2,330 and $2,537 as of June 30, 2025 and December 31, 2024, respectively, included in accounts payable and accrued liabilities on the Company's Consolidated Balance Sheets.

<u>FocusGrowth Term Loan</u>

On August 1, 2024, the Company and TerrAscend USA, Inc., as guarantors, and each of WDB Holding CA, Inc., WDB Holding PA, Inc., Moose Curve Holdings, LLC, Hempaid, LLC and pursuant to a joinder agreement dated September 30, 2024, WDB Holding MI, Inc., including certain of each of their respective subsidiaries, as borrowers (collectively, the "Borrowers"), and FG Agency Lending LLC, as the Administrative Agent entered into a Loan Agreement (the "FG Loan") for a four-year, $140,000 senior-secured term loan. Net proceeds of the FG Loan were received in an amount equal to 95% of the $140,000.

The FG Loan bears interest at 12.75% per annum and matures on August 1, 2028 (the "FG Loan Maturity Date"). The FG Loan is guaranteed by the Company and TerrAscend USA, Inc. and is secured by substantially all of the assets of the Borrowers. Depending on the timing of repayment, an exit fee of between 2.0% and 4.0% of the FG Loan (the "Exit Fee") will be due upon either the prepayment or the FG Loan Maturity Date.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

As of June 30, 2025, there was an outstanding principal amount of $140,000 under the FG Loan.

Subsequent to June 30, 2025, on July 8, 2025, the Incremental Amendment Borrowers (as defined below), became parties to the FG Loan as borrowers pursuant to a joinder agreement, by and among the Incremental Amendment Borrowers and the Agent, which provided for an additional $79,000 upsize to the existing FG Loan (the "FG Loan Amendment"). Additionally, the Amendment provides for an uncommitted term loan facility of up to $35,000 (the "Uncommitted Term Loan Facility"). The full amount of the FG Loan Amendment of $79,000 was drawn on July 8, 2025, $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives (see Note 24).

<u>Pelorus Term Loan</u>

On October 11, 2022, subsidiaries of, TerrAscend, among others, entered into a loan agreement with Pelorus Fund REIT, LLC ("Pelorus") for a single-draw senior secured term loan (the "Pelorus Term Loan") in an aggregate principal amount of $45,478. The Pelorus Term Loan is based on a variable rate tied to the one month Secured Overnight Financing Rate ("SOFR"), subject to a base rate, plus 9.5%, with interest-only payments for the first 36 months and matures on October 11, 2027. The base rate is defined as, on any day, the greatest of: (a) 2.5%, (b) the effective federal funds rate in effect on such day plus 0.5%, and (c) one month Secured Overnight Financing Rate ("SOFR") in effect on such day. The obligations of the borrowers under the Pelorus Term Loan are guaranteed by the Company, TerrAscend USA and certain other subsidiaries of TerrAscend and are secured by all of the assets of TerrAscend's New Jersey businesses and certain assets of TerrAscend's Maryland business, including certain real estate in Maryland. The Pelorus Term Loan is not secured by any of the MD dispensaries.

As of June 30, 2025, there was an outstanding principal amount of $45,478 under the Pelorus Term Loan.

Subsequent to June 30, 2025, on July 8, 2025, the Company retired the Pelorus Term Loan and paid the outstanding principal amount of $45,478 (see Note 24).

<u>Maryland Acquisition Loans</u>

In connection with the acquisition of Derby 1, LLC on June 28, 2023 ("Peninsula"), Hempaid, LLC on June 30, 2023 ("Blue Ridge"), and Herbiculture Inc. on July 10, 2023 ("Herbiculture"), (collectively, the "Maryland Acquisitions"), the Company entered into promissory notes with an aggregate principal amount of $20,625 that bear interest at rates ranging from 7.0% to 10.75% with maturities ranging from June 28, 2025 to June 30, 2027.

As of June 30, 2025, there was an outstanding principal amount of $16,373 under the Maryland Acquisition Loans.

Subsequent to June 30, 2025, the Company retired a series of promissory notes and paid an outstanding principal amount of $13,077 (see Note 24).

<u>Ratio Acquisition Loans</u>

*FG Bridge Loan*

On May 6, 2025, the Company and Ohio Dispensing 1, LLC, a consolidated entity of the Company, completed the acquisition of certain assets of Ratio Cannabis LLC, a dispensary in Ohio (the "Ratio Acquisition"). In connection with the Ratio Acquisition, Ohio Dispensing 1, LLC, and FG Agency Lending LLC, as the Administrative Agent, entered into a Loan Agreement for a $5,208 term loan (the "FG Bridge Loan"). The FG Bridge Loan bears interest at 12.75% per annum and matures on November 2, 2025.

As of June 30, 2025, there was an outstanding principal amount of $5,193 under the FG Bridge Loan

Subsequent to June 30, 2025, on July 8, 2025, the Company retired the FG Bridge Loan and paid the outstanding principal amount of $5,208 (see Note 24).

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

*Ratio Promissory Note*

Additionally, as a part of the Ratio Acquisition, the Company entered into a promissory note for $3,980 bearing 6% interest with a two-year maturity (the "Ratio Promissory Note").

As of June 30, 2025, there was an outstanding principal amount of $3,980 under the Ratio Promissory Note.

<u>Other Loans</u>

*Class A Shares of TerrAscend Growth*

In connection with the 2023 Reorganization (see Note 3), TerrAscend issued $1,000 of Class A shares with a 20% guaranteed annual dividend ("Class A Shares") to an investor (the "Investor") pursuant to the terms of a subscription agreement between TerrAscend and the Investor dated April 20, 2023 (the "Subscription Agreement"). Pursuant to the terms of the Subscription Agreement, TerrAscend holds a call right to repurchase all of the Class A Shares issued to the Investor for an amount equal to the sum of: (a) the Repurchase/Put Price (as defined in the Subscription Agreement); plus (b) the amount equal to 40% of the subscription amount less the aggregate dividends paid to the Investor as of the date of the exercise of the option. In addition, the Investor holds a put right that is exercisable at any time after four months' advanced written notice following the five-year anniversary of the closing of the investment to put all (and only all) of the Class A Shares owned by the Investor to TerrAscend at the Repurchase/Put Price, payable in cash or shares. The instrument is considered as a debt for accounting purposes due to the economic characteristics and risks.

<u>Maturities of loans payable</u>

Stated maturities of loans payable over the next five years are as follows:

---

| | |
|:---|:---|
|  | **June 30, 2025** |
|  | **(In thousands)** |
| 2025 | $346 |
| 2026 | 728 |
| 2027 | 6024 |
| 2028 (1) | 204951 |
| 2029 | 7 |
| Thereafter | 3 |
| Total principal payments | $212059 |
| (1) Balance excludes the Exit Fee, as described above within this note. |  |

---

The Company is subject to financial covenants as a result of its loans payable with various lenders. The Company was in compliance with its debt covenants as of June 30, 2025. In the event that, in future periods, the Company's financial results are below levels required to maintain compliance with any of its covenants, the Company will assess and undertake appropriate corrective initiatives with a view to allowing it to continue to comply with its covenants.

**11.** **Leases** 

The majority of the Company's leases are operating leases used primarily for corporate offices and retail. The operating lease periods generally range from 1 to 24 years. The Company had no finance leases at June 30, 2025 and December 31, 2024.

Amounts recognized in the Consolidated Balance Sheets were as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Operating leases: |  |  |
| &nbsp;&nbsp;Operating lease right-of-use assets | $28890 | $28755 |
| &nbsp;&nbsp;Operating lease liability classified as current | 1265 | 1322 |
| &nbsp;&nbsp;Operating lease liability classified as non-current | 31036 | 30664 |
| **Total operating lease liabilities** | $**32301** | $**31986** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

The Company recognized operating lease expense of $1,254 and $2,478 for the three and six months ended June 30, 2025, respectively, and $1,404 and $2,708 for the three and six months ended June 30, 2024, respectively.

Other information related to operating leases at June 30, 2025 and December 31, 2024 consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
| Weighted-average remaining lease term (years) |  |  |
| &nbsp;&nbsp;Operating leases | 13.3 | 13.2 |
| Weighted-average discount rate |  |  |
| &nbsp;&nbsp;Operating leases | 11.27% | 11.19% |

---

Supplemental cash flow information related to leases are as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Cash paid for amounts included in measurement of operating lease liabilities | $2338 | $4672 |
| Right-of-use assets obtained in exchange for operating lease obligations | 2457 | 655 |

---

Undiscounted lease obligations are as follows:

---

| | |
|:---|:---|
|  | **Operating** |
|  | **(In thousands)** |
| 2025 | $2389 |
| 2026 | 4594 |
| 2027 | 4670 |
| 2028 | 4750 |
| 2029 | 4857 |
| Thereafter | 44051 |
| Total lease payments | 65311 |
| Less: interest | (33010) |
| Total lease liabilities | $32301 |

---

**12.** **Convertible Debt**

The Company's convertible debt consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Convertible debt proceeds, net of transaction costs - Maturing June 2026 | $10098 | $10098 |
| &nbsp;&nbsp;Allocation to conversion option | 3600 | 3600 |
| &nbsp;&nbsp;Allocation to debt | 6498 | 6498 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and accretion | 3723 | 2616 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net carrying amount** | $**10221** | $**9114** |

---

The Company had accrued interest on convertible debt of $1,795 and $1,200 as of June 30, 2025 and December 31, 2024, respectively, included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.

**13.** **Shareholders' equity**

<u>Share Repurchase Authorization</u> 

On August 20, 2024, the Board approved a share repurchase program to repurchase up to $10,000 of Common Shares. The share repurchase program authorizes the Company to repurchase up to 10,000,000 Common Shares of the Company at any time, or from

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

time to time, from August 22, 2024 until August 21, 2025. The share repurchase program authorizes the Company to repurchase up to 65,361 Common Shares daily, which represents 25% of the Company's average daily trading volume on the TSX of 261,445 Common Shares. Any repurchases under the program may be made by means of open market transactions, negotiated block transactions, or otherwise, including pursuant to a repurchase plan administered in accordance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, as amended. The size and timing of any repurchases will depend on price, market and business conditions, and other factors.

As of June 30, 2025, the Company had a total of 8,720,600 Common Shares remaining that can be authorized for repurchase. The following is a summary of the Common Shares that were repurchased for the three and six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands, except per share data)** | **(In thousands, except per share data)** | **(In thousands, except per share data)** | **(In thousands, except per share data)** |
| Total Common Shares repurchased | 535000 |  | 1042500 |  |
| Common Shares canceled | 535000 |  | 1172000 |  |
| Weighted average price per share | $0.29 | $— | $0.37 | $— |
| Total cost | $139 | $— | $360 | $— |
| Excise tax (1) | $7 | $— | $17 | $— |

---

(1) The excise tax accrued in connection with the share repurchases was recorded as an adjustment to the cost basis of repurchased shares in treasury stock and within accrued expenses on the Consolidated Balance Sheets as of June 30, 2025.

<u>Warrants</u>

The following is a summary of the outstanding warrants for Common Shares:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of Common Share Warrants Outstanding** | **Number of Common Share Warrants Exercisable** | **Weighted Average Exercise Price $** | **Weighted Average Remaining Life (years)** |
| **Outstanding, December 31, 2024** | **23370627** | **859012** | $**4.14** | 7.77 |
| Granted |  |  |  |  |
| Expired |  |  |  |  |
| **Outstanding, June 30, 2025** | **23370627** | **859012** | $**4.14** | 7.27 |

---

The following is a summary of the outstanding warrant liabilities that are exchangeable into Common Shares:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of Common Share Warrants Outstanding** | **Number of Common Share Warrants Exercisable** | **Weighted Average Exercise Price $** | **Weighted Average Remaining Life (years)** |
| **Outstanding, December 31, 2024** | **3590334** |  | $**1.95** | 0.48 |
| Granted |  |  |  |  |
| Expired | (3590334) |  |  |  |
| **Outstanding, June 30, 2025** | **—** |  | $**—** | **—** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

**14.** **Share-based compensation plans**

<u>Share-based payments expense</u>

Total share-based payments expense was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Stock options | $746 | $1183 | $1586 | $2087 |
| Restricted share units | 33 | 777 | $707 | 1358 |
| **Total share-based payments** | $**779** | $**1960** | $**2293** | $**3445** |

---

<u>Stock Options</u>

The following table summarizes the stock option activity for the six months ended June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of Stock Options** | **Weighted average remaining contractual life (in years)** | **Weighted Average Exercise Price (per share) $** | **Aggregate intrinsic value** |
| **Outstanding, December 31, 2024** | **16120919** | 5.90 | $**3.13** | $**32** |
| Granted | 762500 |  | 0.42 |  |
| Exercised |  |  |  |  |
| Forfeited | (465696) |  | 4.76 |  |
| Expired | (1470471) |  | 4.20 |  |
| **Outstanding, June 30, 2025** | **14947252** | 5.94 | $**2.84** | $**—** |
| **Exercisable, June 30, 2025** | **10529493** | 4.84 | $**3.43** | $**—** |

---

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between Company's closing stock price on June 30, 2025 and December 31, 2024, respectively, and the exercise price, multiplied by the number of the in-the-money options) that would have been received by the option holders had they exercised their in-the-money options on June 30, 2025 and December 31, 2024, respectively.

The fair value of the various stock options granted were estimated using the Black-Scholes Option Pricing Model (the "Black-Scholes Model") with the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **June 30, 2024** |
| Volatility | 75.76% - 79.89% | 77.70% - 78.31% |
| Risk-free interest rate | 3.86% - 4.12% | 3.18% - 3.76% |
| Expected life (years) | 4.87 - 6.25 | 4.01 - 10.01 |
| Dividend yield | 0.00% | 0.00% |

---

Volatility was estimated by using the historical volatility of the Company's stock price. The expected life in years represents the period of time that the options issued are expected to be outstanding. The risk-free rate is based on U.S. treasury bond issues with a remaining term approximately equal to the expected life of the options. Dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future.

The total estimated fair value of stock options that vested during the six months ended June 30, 2025 and 2024 was $2,837 and $4,594, respectively. As of June 30, 2025, total unrecognized compensation cost related to unvested options was $3,829, which is expected to be recognized over a weighted-average period of 2.10 years.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

*Repricing of Stock Options*

On June 24, 2025 (the "Option Modification Date"), the Board approved a stock option repricing for employees and insiders of the Company (the "Option Repricing") in which the exercise price of certain outstanding options to purchase Common Shares under the Company's stock option plan will be reduced to $0.26 per share, which represented the five-day volume weighted average price of the Common Shares based on the Option Modification Date, subject to meeting a service period requirement of twelve months following the Option Modification Date ("Service Period Requirement"). The Option Repricing with respect to insiders of the Company was also approved by the Company's shareholders at its Annual General Meeting held on June 24, 2025. As a result of the Option Repricing, 8,279,003 shares of vested and unvested stock options outstanding were modified, in accordance with ASC 718, *Stock-Based Compensation,* as of the Option Modification Date resulting in an incremental expense of $868. The vested portion will be recognized on a straight-lined basis over the Service Period Requirement and the unvested portion will be recognized over the remaining vesting periods of each respective award.

<u>Restricted Share Units</u>

The following table summarizes the activities for the RSUs for the six months ended June 30, 2025:

---

| | |
|:---|:---|
|  | **Number of RSUs** |
| **Outstanding, December 31, 2024** | **1600305** |
| Granted | 5907257 |
| Vested | (542087) |
| Forfeited | (5654) |
| **Outstanding, June 30, 2025** | **6959821** |

---

As of June 30, 2025, total unrecognized compensation cost related to unvested RSUs was $3,776, which is expected to be recognized over a weighted-average period of 3.07 years.

**15.** **Non-controlling interest** 

Non-controlling interest consists mainly of a 12.5% minority ownership interest in TerrAscend's New Jersey operations.

The following table summarizes the non-controlling interest activity for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Opening carrying amount | $(144) | $(1756) |
| Capital distributions | (1988) | (7324) |
| Acquisition of non-controlling interest |  | 1374 |
| Net income attributable to non-controlling interest | 2580 | 7562 |
| **Ending carrying amount** | $**448** | $**(144)** |

---

**16.** **Related parties** 

Parties are related if one party has the ability to control or exercise significant influence over the other party in making financing and operating decisions. At June 30, 2025, amounts due to/from related parties consisted of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Loans payable*: As of June 30, 2025, certain funds controlled by Jason Wild, a related party of the Company, held $5,500 of the total loan principal balance of the FG Loan (see Note 10), as a member of the loan syndicate.

**17.** **Income taxes** 

The Company's effective tax rate was 301% and 333% for the three and six months ended June 30, 2025, respectively, and 321% and 1,293% for the three and six months ended June 30, 2024, respectively.

The Company has computed its provision for income taxes based on the actual effective tax rate for the quarter as the Company believes this is the best estimate for the annual effective tax rate. The Company is subject to income taxes in the United States and Canada.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

Significant judgment is required in evaluating the Company's uncertain tax positions and determining the provision for income taxes. The Company recognizes benefits from uncertain tax positions based on the cumulative probability method whereby the largest benefit with a cumulative probability of greater than 50% is recorded. An uncertain tax position is not recognized if it has less than a 50% likelihood of being sustained.

A reconciliation of the beginning and ending amount of unrecognized tax benefits for the period presented:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Balance at beginning of year** | $**148979** | $**84485** |
| Increase based on tax positions related to current periods | 17728 | 37278 |
| Increase based on tax positions related to prior periods |  | 40986 |
| Settlements with tax authorities |  | (13770) |
| **Balance at end of year** | $**166707** | $**148979** |

---

A reconciliation of the beginning and ending amount of uncertain tax liabilities, inclusive of accruals for related penalties and interest, for the period presented:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Balance, beginning of year** | $**106991** | $**79627** |
| Increases based on tax positions related to prior years | 4332 | 4536 |
| Additions based on tax positions related to current year | 12514 | 26825 |
| Additions based on refunds received related to prior years | 16 | 10 |
| Release of tax payments on deposit and other | (1161) | (4007) |
| **Ending carrying amount (1)** | $**122692** | $**106991** |

---

(1) Related to uncertain tax liabilities, the Company accrued $10,232 in interest and $7,385 in penalties as of June 30, 2025, and $8,006 in interest and $4,803 in penalties as of December 31, 2024.

The increase in uncertain tax positions is primarily due to legal interpretations that challenge the application of Section 280E of the Code to the Company ("280E Tax Position"). The Company believes it is reasonably possible that the unrecognized tax benefits will increase over the next 12 months due to its 280E Tax Position.

During 2024, certain of the Company's amended federal income tax returns were selected for routine examinations by the Internal Revenue Service. As of June 30, 2025, there have been no material developments related to these examinations. The Company does not currently anticipate completion of the audits within the next twelve months.

**18.** **General and administrative expenses**

The Company's general and administrative expenses were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Salaries and wages | $12086 | $11497 | $24061 | 22801 |
| Office and general | 2706 | 2868 | 5281 | 5815 |
| Professional fees | 2244 | 3458 | 4395 | 6040 |
| Lease expense | 1179 | 1413 | 2333 | 2615 |
| Share-based compensation | 779 | 1960 | 2293 | 3445 |
| Board of directors cash compensation | 398 |  | 398 |  |
| Facility and maintenance | 507 | 429 | 1016 | 981 |
| Sales and marketing | 888 | 1027 | 1679 | 2012 |
| Provision for expected credit losses | 193 | (20) | 673 |  |
| **Total** | $**20980** | $**22632** | $**42129** | $**43709** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

**19.** **Revenue, net** 

The Company's disaggregated net revenue by source, primarily due to the Company's contracts with its external customers was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Retail | $43665 | $43263 | $84497 | $86120 |
| Wholesale | 21341 | 23933 | 44812 | 50351 |
| **Total** | $**65006** | $**67196** | $**129309** | $**136471** |

---

For the three and six months ended June 30, 2025 and 2024, the Company did not have any single customer that accounted for 10% or more of the Company's revenue.

**20.** **Finance and other expenses**

The Company's finance and other expenses included the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Interest | $6960 | $7002 | $13643 | $13594 |
| Accretion | 2002 | 1743 | 3740 | 3546 |
| Other income | (215) | (184) | (301) | (337) |
| **Total** | $**8747** | $**8561** | $**17082** | $**16803** |

---

**21.** **Segment information**

<u>Operating Segment</u>

The Company has determined that it operates as one reportable segment focused on the production and sale of cannabis products. While the Company manages its operations through state-level operating segments, these segments have been aggregated into one reportable segment due to similar long-term economic characteristics and other required criteria of similarity outlined in ASC 280, *Segment Reporting*, and in accordance with ASU 2023-07. The Chief Operating Decision Maker ("CODM") was determined to be the Chief Executive Officer of the Company. The CODM regularly evaluates the performance of the single reportable segment using gross profit margin as its closest measure to GAAP. Gross margin is a measure that is calculated as total revenue minus cost of goods sold, divided by total revenue. The CODM monitors this metric to assess the efficiency of the Company's production and distribution processes, as well as the effectiveness of pricing strategies.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Revenue, net** | $**65006** | $67196 | $129309 | $136471 |
| **Cost of sales** | 31771 | 33837 | 61393 | 68942 |
| **Gross profit** | 33235 | 33359 | 67916 | 67529 |
| ***Gross profit margin*** | ***51.1***<br>*%*** | ***49.6***<br>*%*** | ***52.5***<br>*%*** | ***49.5***<br>*%*** |

---

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

<u>Assets</u>

The measure of reportable segment assets is consistent with the presentation of total consolidated assets as reported on the Consolidated Balance Sheets.

<u>Geography</u> 

The Company has subsidiaries located in Canada and the United States. For the three and six months ended June 30, 2025, net revenue was primarily generated from sales in the United States. As a result of the 2023 Reorganization (see Note 3), the Company consolidated its retail location in Canada and generated net revenue of $219 and $397 for the three and six months ended June 30, 2025, respectively, and $274 and $538 for the three and six months ended June 30, 2024, respectively.

The Company had non-current assets by geography of:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| United States | $438829 | $429745 |
| Canada | 95 | 598 |
| **Total** | $**438924** | $**430343** |

---

**22.** **Financial instruments and risk management** 

<u>Assets and liabilities measured at fair value</u>

Financial instruments recorded at fair value are estimated by applying a fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy is summarized as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 1 - quoted prices (unadjusted) in active markets for identical assets and liabilities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 2 - inputs other than quoted prices that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 3 - inputs for assets and liabilities not based upon observable market data

The following table represents the fair value amounts of financial assets and financial liabilities:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **At June 30, 2025** | **At June 30, 2025** | **At June 30, 2025** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
|  | **Level 1** | **Level 2** | **Level 3** | **Level 1** | **Level 2** | **Level 3** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Assets** |  |  |  |  |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $26672 |  |  | $26381 |  |  |
| &nbsp;&nbsp;Restricted cash | 110 |  |  | 606 |  |  |
| **Total Assets** | $**26782** | $**—** | $**—** | $**26987** | $**—** | $**—** |
| **Liabilities** |  |  |  |  |  |  |
| &nbsp;&nbsp;Contingent consideration payable |  | 1672 |  |  | 3293 |  |
| &nbsp;&nbsp;Detachable warrants |  | - |  |  | 451 |  |
| &nbsp;&nbsp;Bifurcated conversion options |  | 178 |  |  | 92 |  |
| **Total Liabilities** | $**—** | $**1850** | $**—** | $**—** | $**3836** | $**—** |

---

There were no transfers between the levels of fair value hierarchy during the three and six months ended June 30, 2025.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within levels of the fair value hierarchy are presented below:

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

<u>Level 1</u>

Includes cash, cash equivalents, and restricted cash represent financial instruments for which the carrying amount approximates fair value due to their short-term maturities.

<u>Level 2</u>

Includes detachable warrants, bifurcated conversion options, and a contingent consideration, which are valued using the Black-Scholes Model with observable market inputs such as stock price, historical volatility, risk-free rate, and expected term. These inputs are derived from market data and do not require significant judgment.

*Detachable Warrants*

The detachable warrants expired during the second quarter of 2025.

*Bifurcated conversion options*

The conversion options have been measured at fair value as of June 30, 2025. Key inputs and assumptions used in the Black-Scholes Model were as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
| Common Stock Price of TerrAscend Corp. | $0.28 | $0.65 |
| Option exercise price | $2.01 | $2.01 |
| Annual volatility | 109.9% | 86.9% |
| Annual risk-free rate | 3.96% | 4.25% |
| Expected term (in years) | 0.98 - 1.09 | 1.48 - 1.59 |

---

The following table summarizes the changes in the detachable warrants and bifurcated conversion options:

---

| | |
|:---|:---|
| **Balance at December 31, 2024** | $**543** |
| Fair value gain on revaluation of warrants and conversion option | (376) |
| Effects of movements in foreign exchange | 11 |
| **Balance at June 30, 2025** | $**178** |

---

*Contingent Consideration Payable*

The contingent consideration has been measured at fair value as of June 30, 2025. Key inputs and assumptions used in the Black-Scholes Model were as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
| Common Stock Price of TerrAscend Corp. | $0.28 | $0.65 |
| Option exercise price | $0.38 | $1.33 |
| Annual volatility | 113.6% | 106.6% |
| Annual risk-free rate | 4.29% | 4.24% |
| Expected term (in years) | 0.55 | 1.05 |

---

**23.** **Commitments and contingencies**

<u>Commitments</u>

On May 5, 2025, the Company signed an agreement to acquire equity interests in, and fully operate, Union Chill Cannabis Company LLC, a dispensary in New Jersey for total consideration of $13,000, which will be comprised of $4,000 in cash and a convertible promissory note for $9,000. The transaction is subject to customary closing conditions and regulatory approvals.

------

TerrAscend Corp.

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** 

*(Amounts expressed in thousands of United States dollars, except for share and per share amounts)*

<u>Legal proceedings</u>

In the ordinary course of business, the Company is involved in a number of lawsuits incidental to its business, including litigation related to intellectual property, product liability, employment, and commercial matters. Although it is difficult to predict the ultimate outcome of these matters, management believes that any ultimate liability would not have a material adverse effect on the Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. At June 30, 2025, there were no pending lawsuits that could reasonably be expected to have a material effect on the results of the Company's Consolidated Financial Statements.

**24.** **Subsequent events**

On July 8, 2025, TerrAscend Growth Corp., TerrAscend USA, Inc., TerrAscend NJ LLC, TER Holding MD, Inc., and WDB Holding MD, Inc., including certain of each of their respective subsidiaries, and other borrowers, all of which are entities that are consolidated in the financial statements of the Company (collectively, the "Incremental Amendment Borrowers"), became parties to the FG Loan as borrowers pursuant to the FG Loan Amendment, which provided for an additional $79,000 upsize to the existing FG Loan which bears interest at 12.75% per annum and matures on August 1, 2028. The full amount of the FG Loan Amendment of $79,000 was drawn on July 8, 2025, and $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives. As a result, the outstanding obligation under the Pelorus Term Loan and certain other indebtedness of the Company were repaid in full and subsequently terminated. In addition, the FG Loan Amendment provides for an Uncommitted Term Loan Facility of up to $35,000. Certain funds controlled by the Company's Executive Chairman, Jason Wild, a related party of the Company, have invested approximately $1,600 under the FG Loan.

On July 15, the Company drew $3,000 of the Uncommitted Term Loan Facility.

------

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion and analysis of financial condition and results of operations of TerrAscend Corp. (the "Issuer"), its subsidiaries, TerrAscend Growth Corp. ("TerrAscend") and its subsidiaries (collectively, the "Company") should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements ("Consolidated Financial Statements") and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission, (the "SEC"), on March 6, 2025, (the "Annual Report"). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q including information with respect to the Company's plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under "Risk Factors" in the Company's Annual Report, its actual results could differ materially from the results described in or implied by the "Cautionary Note Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in the following discussion and analysis.* 

*Unless otherwise noted, dollar amounts in this Item 2 are in thousands of U.S. dollars.*

This Management's Discussion and Analysis ("MD&A") of the financial condition and results of operations of the Company is for the three and six months ended June 30, 2025 and 2024 and the accompanying notes for each respective period.

**<u>Overview</u>**

The Company is a leading North American cannabis company. The Company has vertically integrated licensed operations in Pennsylvania, New Jersey, Michigan, Maryland and California and a retail operation in Ohio. In addition, the Company has retail operations in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada. Notwithstanding the fact that various states in the United States have implemented medical marijuana laws or have otherwise legalized the use of cannabis, the use of cannabis remains illegal under U.S. federal law for any purpose, by way of the Controlled Substances Act of 1970.

The Company operates under one reportable segment, which is the cultivation, production and sale of cannabis products.

The Company owns a portfolio of operating businesses, including:

• TerrAscend New Jersey ("TerrAscend NJ"), a majority owned operation with three dispensaries, and a cultivation/processing facility;

• TerrAscend Maryland ("TerrAscend MD"), a wholly-owned operation with four dispensaries, and a cultivation/processing facility;

• TerrAscend Pennsylvania ("TerrAscend PA"), a wholly-owned operation with six dispensaries, and a cultivation/processing facility;

• TerrAscend California ("TerrAscend CA"), a wholly-owned operation with four dispensaries, and a cultivation facility;

• TerrAscend Ohio ("TerrAscend OH"), a wholly-owned operation with one dispensary; and

• TerrAscend Canada Inc. ("TerrAscend Canada"), a cannabis retailer in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada ("Cookies Canada").

• TerrAscend Michigan ("TerrAscend MI"), a wholly-owned operation with twenty dispensaries, one cultivation facility, one processing facility, and two cultivation/processing facilities which were classified as discontinued operations during the six months ended June 30, 2025.

**<u>Recent Developments</u>** 

• On June 27, 2025, the Company received approval from the board of directors of TerrAscend Corp. (the "Board"), together with TerrAscend Corp.'s consolidated entities, and is currently engaged in an active program to sell the assets of TerrAscend MI, which is expected to be substantially completed in the second half of 2025. As part of the exit plan, the Company intends to sell all of the Company's Michigan assets, including four cultivation and processing facilities, twenty retail dispensaries, and other assets. The actions are expected to include an overall reduction of approximately 21% of the Company's workforce of approximately 1,200 as of June 30, 2025, with most of this reduction expected to occur by the end of the fourth quarter of fiscal year 2025. TerrAscend MI is presented as discontinued operations and has been excluded from continuing operations for all periods presented. Refer to Note 7 in the Consolidated Financial Statements for additional information.

------

• On May 6, 2025, the Company and a consolidated entity completed the acquisition of certain assets of Ratio Cannabis LLC, a dispensary in Ohio. Under the terms of the purchase agreements entered into in connection with the acquisition, each dated as of March 14, 2025, the Company and a consolidated entity acquired certain assets of Ratio Cannabis for total consideration of $10,300, which was comprised of $5,000 in cash, $1,320 in Common Shares and a seller's note for $3,980 bearing 6% interest with a two-year maturity. The number of Common Shares issued as part of the consideration was calculated based on the twenty (20)-day volume-weighted average price of the Common Shares on the OTCQX for the period ending on May 5, 2025, resulting in the issuance of 4,570,637 Common Shares by the Company on May 6, 2025.

• On May 5, 2025, the Company signed an option agreement to acquire equity interests in, and fully operate, Union Chill Cannabis Company LLC, a dispensary in New Jersey for total consideration of $13,000, which will be comprised of $4,000 in cash and a convertible promissory note for $9,000. The transaction is subject to customary closing conditions and regulatory approvals.

**<u>Subsequent Transactions</u>**

• On July 18, 2025, Keith Stauffer's resignation as the Company's Chief Financial Officer became effective.

• On July 15, 2025, the Company drew $3,000 of the Uncommitted Term Loan Facility.

• On July 8, 2025, the Incremental Amendment Borrowers, all of which are entities that are consolidated in the financial statements of the Company, became parties to the FG Loan as borrowers pursuant to the FG Loan Amendment, which provided for an additional $79,000 upsize to the existing FG Loan which bears interest at 12.75% per annum and matures on August 1, 2028. The full amount of the FG Loan Amendment of $79,000 was drawn on July 8, 2025, $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives. As a result, the outstanding obligation under the Pelorus Term Loan were repaid in full and subsequently terminated. In addition, the FG Loan Amendment provides for an Uncommitted Term Loan Facility of up to $35,000. Certain funds controlled by the Company's Executive Chairman, Jason Wild, a related party of the Company, have invested approximately $1,600 under the FG Loan.

**<u>Components of Results of Operations</u>**

The following discussion sets forth certain components of the Company's unaudited condensed consolidated statements of comprehensive loss as well as factors that impact those items.

***Revenue, net***

The Company generates revenue from the sale of cannabis products, brands, and services to the U.S. and Canadian markets. Revenues consist of wholesale and retail sales in the legal medical and adult-use market across Canada and in several U.S. states where cannabis has been legalized for medical or adult-use cannabis.

***Cost of sales***

Cost of sales primarily consists of expenses related to providing cannabis products and services to the Company's customers, including personnel-related expenses, the depreciation of property and equipment, amortization of acquired intangible assets, certain royalties, and other overhead costs.

***Operating Expenses***

<u>General and administrative</u>

General and administrative ("G&A") expenses consist primarily of personnel costs related to finance, human resources, legal, certain royalties, and other administrative functions. Additionally, G&A expenses include professional fees to third parties, as well as marketing expenses. Moreover, G&A expenses include share-based compensation on options, restricted stock units and warrants. The Company expects that G&A expenses will increase in absolute dollars as the business grows.

------

<u>Amortization and depreciation</u>

Amortization and depreciation includes the amortization of intangible assets. Amortization is calculated on a straight-line basis over the following terms:

---

| | |
|:---|:---|
| Brand intangibles- indefinite lives | Indefinite useful lives |
| Software | 5 years |
| Licenses | 15-30 years |

---

Depreciation of property and equipment is calculated on a straight-line basis over the estimated useful life of the asset using the following terms:

---

| | |
|:---|:---|
| Buildings and improvements | 15-30 years |
| Land | Not depreciated |
| Machinery & equipment | 5-15 years |
| Office furniture & production equipment | 3-5 years |
| Right of use assets | Lease term |
| Assets in process | Not depreciated |

---

***Loss from revaluation of contingent consideration***

As a result of certain acquisitions, the Company recognized contingent consideration liabilities related to price protection provisions. These provisions may require the Company to issue additional Common Shares to the sellers if subsequent prices fall below certain agreed upon prices. These contingent consideration liabilities are remeasured to fair value at the end of each reporting period using the Black-Scholes Model in which a gain or loss is recognized as a result of the revaluation.

***(Gain) loss on fair value of derivative liabilities***

The Company issued convertible debt that contains embedded derivative features, which were bifurcated and accounted for separately as derivative instruments. These derivative liabilities are remeasured to fair value at the end of each reporting period using the Black-Scholes Model in which a gain or loss is recognized as a result of the revaluation.

***Finance and other expenses***

Finance and other expenses consist primarily of interest and accretion expense on the Company's outstanding debt obligations.

***Unrealized and realized foreign exchange loss***

Unrealized and realized foreign exchange loss represents the loss recognized on the remeasurement of USD denominated cash and other assets recorded in the Canadian dollars functional currency at the Company's Canadian operations.

***Provision for income taxes***

Provision for income taxes consists of U.S. federal and state income taxes in certain jurisdictions in which the Company conducts business.

------

**<u>Results of Operations - Three Months Ended June 30, 2025 and June 30, 2024</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

*<u>Continuing Operations</u>*

The following tables represent the Company's results of operations for the three months ended June 30, 2025 and 2024.

***Revenue, net***

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Revenue, net** | $**65006** | $**67196** |
| $ change | $(2190) |  |
| % change | -3% |  |

---

Revenue decreased by $2,190, or 3% from $67,196 for the three months ended June 30, 2024 to $65,006 for the three months ended June 30, 2025. The decrease was primarily due to a $2,592 decline in wholesale revenue, partially offset by a $402 increase in retail revenue.

The $2,592 decrease in wholesale revenue consisted of a $4,438 decline across multiple markets primarily due to price compression. This was partially offset by a $1,846 increase driven by market share growth in Maryland supported by cultivation projects aimed at scaling operations and delivering enhanced product quality.

The $402 increase in retail revenue consisted of $1,242 attributable to acquisitive growth and $1,232 related to strong consumer demand in emerging markets. This was offset by a $2,072 decrease across other markets primarily due to a decrease in foot traffic and average order sizes.

***Cost of sales*** 

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Cost of sales** | $**31771** | $**33837** |
| $ change | $(2066) |  |
| % change | -6% |  |
| Cost of sales as a % of revenue | 49% | 50% |

---

The decrease of $2,066, in cost of sales for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024 was mainly due to a decrease in sales volume. Despite the decline, cost of sales as a percentage of revenue remained relatively flat due to reduced unit costs and improved cost absorption.

------

***General and administrative expense***

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| General and administrative expense | $20980 | $22632 |
| $ change | $(1652) |  |
| % change | -7% |  |

---

The decrease of $1,652 in general and administrative expense for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024, is primarily driven by a reduction in professional fees and stock-based compensation, slightly offset by an increase in provision for expected credit losses.

***Loss from revaluation of contingent consideration***

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| (Gain) loss from revaluation of contingent consideration | $(34) | $1827 |
| $ change | $(1861) |  |
| % change | -102% |  |

---

The gain of $34 for the three months ended June 30, 2025, compared to a loss of $1,827 for the three months ended June 30, 2024, reflects a decrease in the fair value of the contingent consideration liability. This change was primarily driven by the Company's issuance of Common Shares, which triggered a reduction in the exercise price under the price protection agreement and significantly lowered the likelihood of additional Common Shares being issued.

***Gain on fair value of derivative liabilities***

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Gain on fair value of derivative liabilities | $(279) | $(2922) |
| $ change | $2643 |  |
| % change | -90% |  |

---

The lower gain on derivative liabilities of $279 for the three months ended June 30, 2025 compared the gain of $2,922 for the three months ended June 30, 2024, reflects a reduced fair value impact, as the Company's stock price had already declined significantly in the prior period. As the derivative instruments remain out of the money and the stock price stabilizes at lower levels, subsequent remeasurements result in smaller gains. The warrant liability also expired in the three months ended June 30, 2025.

***Provision for income taxes*** 

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Provision for income taxes | $9598 | $9126 |
| $ change | $472 |  |
| % change | 5% |  |

---

The provision for income taxes remained relatively flat with a increase of $472 from $9,126 for the three months ended June 30, 2024 compared to $9,598 for the three months ended June 30, 2025.

------

*<u>Discontinued Operations</u>*

***Discontinued Operations*** 

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| (Loss) income from discontinued operations, net of tax | $(41701) | $48 |
| $ change | $(41749) |  |
| % change | 86977% |  |

---

The change in (loss) income from discontinued operations, net of tax from $48 for the three months ended June 30, 2024 as compared to the loss from discontinued operations, net of tax of $41,701 was primarily due to a $34,959 impairment charge that was recognized in the three months ended June 30, 2025. The impairment charge was attributable to the Company's expedited sales strategy, constructions in process that will no longer be completed, and the continued increase of competition in the Michigan market. The remaining increase in loss resulted from continued market saturation and price compression in Michigan which negatively impacted gross margins.

**<u>Results of Operations - Six Months Ended June 30, 2025 and June 30, 2024</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

*<u>Continuing Operations</u>*

The following tables represent the Company's results of operations for the six months ended June 30, 2025 and 2024.

***Revenue, net***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Revenue, net** | $**129309** | $**136471** |
| $ change | $(7162) |  |
| % change | -5% |  |

---

Revenue decreased by $7,162, or 5% from $136,471 for the six months ended June 30, 2024 to $129,309 for the six months ended June 30, 2025. The decrease was primarily due to a $5,539 decline in wholesale revenue a $1,623 decline in retail revenue.

Wholesale revenue for the six months ended June 30, 2025 and June 30, 2024, reflected similar trends to the three month ended periods previously mentioned with declines across multiple markets primarily due to price compression partially offset by an increase driven by market share growth in Maryland from cultivation projects focused on expansion and high product quality.

Retail revenue for the six months ended June 30, 2025 and June 30, 2024, also followed similar trends to the three month ended periods previously mentioned with positive acquisitive growth and strong consumer demand in emerging markets, offset by lower foot traffic and reduced average order sizes in certain markets.

***Cost of sales*** 

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| **Total cost of sales** | $**61393** | $**68942** |
| $ change | $(7549) |  |
| % change | -11% |  |
| Cost of sales as a % of revenue | 47% | 51% |

---

------

The decrease of $7,549, in cost of sales for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 was mainly due to a decrease in sales volume. Cost of sales as a percentage of revenue decreased by 4% due to reduced unit costs and improved cost absorption on higher year-to-date sales.

***General and administrative expense***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| General and administrative expense | $42129 | $43709 |
| $ change | $(1580) |  |
| % change | -4% |  |

---

The decrease of $1,580 in general and administrative expense for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 reflected similar trends to the three month ended periods previously mentioned with a reduction in professional fees and stock-based compensation, slightly offset by an increase in provision for expected credit losses.

***Loss from revaluation of contingent consideration***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Loss from revaluation of contingent consideration | $346 | $3220 |
| $ change | $(2874) |  |
| % change | -89% |  |

---

The loss of $346 for the six months ended June 30, 2025, compared to a loss of $3,220 for the six months ended June 30, 2024, reflects a decrease in the fair value of the contingent consideration liability. This change was primarily driven by the Company's issuance of Common Shares, which triggered a reduction in the exercise price under the price protection agreement and significantly lowered the likelihood of additional Common Shares being issued. There was also an expiration of a contingent consideration liability during the six months ended June 30, 2025.

***Gain on fair value of derivative liabilities***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Gain on fair value of derivative liabilities | $(376) | $(1939) |
| $ change | $1563 |  |
| % change | -81% |  |

---

The lower gain on derivative liabilities of $376 for the six months ended June 30, 2025 compared the gain of $1,939 for the six months ended June 30, 2024, reflects a reduced fair value impact, as the Company's stock price had already declined significantly in the prior period. As the derivative instruments remain out of the money and the stock price stabilizes at lower levels, subsequent remeasurements result in smaller gains. The warrant liability also expired in the six months ended June 30, 2025.

***Provision for income taxes*** 

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Provision for income taxes | $20105 | $16779 |
| $ change | $3326 |  |
| % change | 20% |  |

---

The change in provision for income taxes from $16,779 for the six months ended June 30, 2024 as compared to a provision for income taxes of $20,105 for the six months ended June 30, 2025 was primarily driven by accrued interest and penalties.

------

*<u>Discontinued Operations</u>*

***Discontinued Operations*** 

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Loss from discontinued operations, net of tax | $(46305) | $(5607) |
| $ change | $(40698) |  |
| % change | 726% |  |

---

The change in loss from discontinued operations, net of tax from $5,607 for the six months ended June 30, 2024 as compared to the loss from discontinued operations, net of tax of $46,305 reflected similar trends to the three month ended periods previously mentioned with a $34,959 impairment charge that was recognized in the six months ended June 30, 2025 attributable to the Company's expedited sales strategy, constructions in process that will no longer be completed, and the continued increase of competition in the Michigan market and continued market saturation and price compression in Michigan which negatively impacted gross margins.

**<u>Liquidity and Capital Resources</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
| Cash and cash equivalents | $26672 | $26381 |
| Restricted Cash | 110 | 606 |
| Current assets | 133083 | 176888 |
| Non-current assets | 438924 | 430343 |
| Current liabilities | 91663 | 91049 |
| Non-current liabilities | 361957 | 339366 |
| Working capital | 41420 | 85839 |
| Total shareholders' equity | $118387 | $176816 |

---

The calculation of working capital provides additional information and is not defined under accounting principles generally accepted in the United States of America ("GAAP"). The Company defines working capital as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP.

Since its inception, the Company's primary sources of capital have been through the issuance of equity securities or debt facilities, and the Company has received aggregate net proceeds from such transactions totaling $787,388 as of June 30, 2025.

The Company expects to fund any additional future requirements through the following sources of capital:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•cash from ongoing operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•market offerings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•additional debt from additional creditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•sale of real property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•sale leaseback transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•exercise of options and warrants.

The Company had $212,059 in principal amounts of loans payable at June 30, 2025. Of this amount, $703 are due within the next twelve months.

The Company entered into leases for certain premises and offices for which it owes monthly lease payments. The Company had $65,311 in lease obligations. Of this amount, $4,687 are due in the next twelve months.

The Company's undiscounted contingent consideration payable was $1,672 at June 30, 2025, which is due in the next twelve months. The contingent consideration payable relates to the Company's acquisition of the remaining 50.1% equity in both State Flower and three Apothecarium dispensaries in California. The contingent consideration is based upon the price protection of Common Shares issued

------

under the terms of the applicable acquisition agreement. The contingent consideration is measured at fair value using the Black-Scholes Model and revalued at the end of each reporting period.

At June 30, 2025, the Company had accounts payable and accrued liabilities of $37,008 and corporate income taxes payable of $12,694.

The Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's results of operations or financial condition, including and without limitation, such consideration as liquidity and capital resources.

The Company intends to meet its capital commitments through any or all of the sources of capital noted above. The Company's objective with respect to its capital management is to ensure it has sufficient cash resources to maintain its ongoing operations and finance future obligations.

**<u>Debt Facilities</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

---

| | | |
|:---|:---|:---|
|  | **Principal Paid during the Six Months Ended June 30, 2025** | **Principal Outstanding as of June 30, 2025** |
|  | **(In thousands)** | **(In thousands)** |
| FocusGrowth Term Loan | $— | $140000 |
| Pelorus Term Loan |  | 45478 |
| Maryland Acquisition Loans | 1963 | 16373 |
| FG Bridge Loan |  | 5193 |
| Ratio Promissory Note |  | 3980 |
| Other Loans | 3 | 1035 |
| &nbsp;&nbsp;Total | $**1966** | $**212059** |

---

***FocusGrowth Term Loan***

On August 1, 2024, the Company and TerrAscend USA, Inc., as guarantors, and each of WDB Holding CA, Inc., WDB Holding PA, Inc., Moose Curve Holdings, LLC, Hempaid, LLC and, pursuant to a joinder agreement dated September 30, 2024, WDB Holding MI, Inc., including certain of each of their respective subsidiaries, as borrowers, and FG Agency Lending LLC, as the Administrative Agent entered into a Loan Agreement for a four-year, $140,000 senior-secured term loan Net proceeds of the FG Loan were received in an amount equal to 95% of the $140,000.

The FG Loan bears interest at 12.75% per annum and matures on August 1, 2028. The FG Loan is guaranteed by the Company and TerrAscend USA, Inc. and is secured by substantially all of the assets of the Borrowers. Depending on the timing of repayment, an exit fee of between 2.0% and 4.0% of the outstanding principal balance of the FG Loan will be due upon either the date of prepayment or the FG Loan Maturity Date.

As of June 30, 2025, there was an outstanding principal amount of $140,000 under the FG Loan.

Subsequent to June 30, 2025, TerrAscend Growth Corp., TerrAscend USA, Inc., TerrAscend NJ LLC, TER Holding MD, Inc., and WDB Holding MD, Inc., including certain of each of their respective subsidiaries, and other borrowers, all of which are entities that are consolidated in the financial statements of the Company, became parties to the FG Loan as borrowers pursuant to a joinder agreement, and through the FG Loan Amendment, which provided for an additional $79,000 upsize to the existing FG Loan. Additionally, the Amendment provides for the $35,000 Uncommitted Term Loan Facility. The full amount of the FG Loan Amendment of $79,000 was drawn on July 8, 2025, $68,000 of which was used to retire the Pelorus Term Loan, and certain other indebtedness of the Company, in addition to being used for future growth initiatives.

On July 15, 2025, the Company drew $3,000 of the Uncommitted Term Loan Facility.

***Pelorus Term Loan***

On October 11, 2022, subsidiaries of TerrAscend, among others, entered into a loan agreement with Pelorus Fund REIT, LLC for a single-draw senior secured term loan in an aggregate principal amount of $45,478. The Pelorus Term Loan is based on a variable rate tied to one month SOFR, subject to a base rate, plus 9.5%, with interest-only payments for the first 36 months and matures on October 11, 2027. The base rate is defined as, on any day, the greatest of: (i) 2.5%, (b) the effective federal funds rate in effect on such day plus

------

0.5%, and (c) one month SOFR in effect on such day. The obligations of the borrowers under the Pelorus Term Loan are guaranteed by the Company, TerrAscend USA and certain other subsidiaries of the Company and are secured by all of the assets of TerrAscend's New Jersey businesses and certain assets of TerrAscend's Maryland business, including certain real estate in Maryland. The Pelorus Term Loan is not secured by any of the MD dispensaries.

On April 17, 2023, TerrAscend NJ agreed to an amendment to the Pelorus Term Loan to, among other things: (i) permit changes necessary for the TSX Transaction (as defined in the Pelorus Term Loan), and (ii) waive certain tax provisions. On June 22, 2023, TerrAscend NJ agreed to a further amendment to the Pelorus Term Loan to permit the Company to incur certain indebtedness. This amendment was not considered an extinguishment of debt under ASC 470, *Debt*.

As of June 30, 2025, there was an outstanding principal amount of $45,478 under the Pelorus Term Loan.

Subsequent to June 30, 2025, on July 8, 2025, the Company retired the Pelorus Term Loan and paid the outstanding principal amount of $45,478.

***Maryland Acquisition Loans***

In connection with the Maryland Acquisitions, the Company entered into a series of promissory notes with an aggregate principal amount of $20,625 that bear interest at rates ranging from 7.0% to 10.75% with maturity dates ranging from June 28, 2025 to June 30, 2027.

As of June 30, 2025, there was an outstanding principal amount of $16,373 under the promissory notes related to the Maryland acquisitions.

Subsequent to June 30, 2025, on July 8, 2025, the Company retired a series of promissory notes and paid an outstanding principal amount of $12,877.

***Ratio Acquisition Loans***

On May 6, 2025, the Company and Ohio Dispensing 1, LLC, a consolidated entity of the Company, completed the acquisition of certain assets of Ratio Cannabis LLC, a dispensary in Ohio. In connection with the Ratio Acquisition, Ohio Dispensing 1, LLC, and FG Agency Lending LLC, as the Administrative Agent entered into a Loan Agreement for a $5,208 term loan. The FG Bridge Loan bears interest at 12.75% per annum and matures on November 2, 2025.

As of June 30, 2025, there was an outstanding principal amount of $5,193 under the FG Bridge Loan.

Subsequent to June 30, 2025, the Company retired the FG Bridge Loan and paid the outstanding principal amount of $5,280.

Additionally, as a part of the Ratio Acquisition, the Company entered into a promissory note for $3,980 bearing 6% interest with a two-year maturity.

As of June 30, 2025, there was an outstanding principal amount of $3,980 under the Ratio Promissory Note.

***Class A Share of TerrAscend Growth*** 

In connection with the listing of the Common Shares on the TSX, the Company reorganized its ownership structure to segregate the Company's Canadian retail operations from TerrAscend's cultivation and manufacturing operations in the United States. As a result, TerrAscend issued Class A Shares to the Investor pursuant to the terms of the Subscription Agreement. Pursuant to the terms of the Subscription Agreement, TerrAscend holds a call right to repurchase all of the Class A Shares issued to the Investor for an amount equal to the sum of: (a) the Repurchase/Put Price (as defined in the Subscription Agreement); plus (b) the amount equal to 40% of the subscription amount less the aggregate dividends paid to the Investor as of the date of the exercise of the option. In addition, the Investor holds a put right that is exercisable at any time after four months' advanced written notice following the five-year anniversary of the closing of the investment to put all (and only all) of the Class A Shares owned by the Investor to TerrAscend at the Repurchase/Put Price, payable in cash or shares. The instrument is considered as a debt for accounting purposes due to the economic characteristics and risks. As of June 30, 2025, there was an outstanding principal amount of $1,000.

------

**<u>Share Repurchases</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

On August 20, 2024, the Board approved a share repurchase program to repurchase up to $10,000 of Common Shares. The share repurchase program authorizes the Company to repurchase up to 10,000,000 Common Shares of the Company at any time, or from time to time, from August 22, 2024 until August 21, 2025. The share repurchase program authorizes the Company to repurchase up to 65,361 Common Shares daily, which represents 25% of the Company's average daily trading volume on the TSX of 261,445 Common Shares. Any repurchases under the program may be made by means of open market transactions, negotiated block transactions, or otherwise, including pursuant to a repurchase plan administered in accordance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, as amended. The size and timing of any repurchases will depend on price, market and business conditions, and other factors.

During the second quarter of 2025, the Company repurchased 535,000 common shares under the share repurchase program for total consideration of approximately $157. As of June 30, 2025, the Company had a total of 8,720,600 Common Shares remaining that can be authorized for repurchase.

**<u>Cash Flows</u>** 

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

***Cash flows provided by operating activities***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| Net cash provided by operating activities | $10821 | $26139 |

---

The decrease of $15,318 in net cash provided by operating activities for the six months ended June 30, 2025 as compared to six months ended June 30, 2024 is primarily driven by an increase in working capital including a reduction of accounts payable and an increase in income taxes paid.

***Cash flows used in investing activities***

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| Net cash used in investing activities | $(11118) | $(4843) |

---

The increase of $6,275 in net cash used in investing activities for the six months ended June 30, 2025 as compared to six months ended June 30, 2024 is primarily driven by the cash consideration paid of $5,261 for the Ratio Cannabis acquisition in the second quarter of 2025.

***Cash flows provided by (used in) financing activities*** 

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
| Net cash provided by (used in) financing activities | $283 | $(16542) |

---

The change of $16,825 in net cash provided by (used in) financing activities for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 is primarily driven by $5,000 of loan proceeds, net of transaction costs, related to the Ratio Cannabis acquisition. The change also reflects fewer loan principal payments due during the six months ended June 30, 2025 as a result of debt refinancing and paydowns completed in 2024.

------

**<u>Reconciliation of Non-GAAP Measures</u>**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) Free cash flow from net cash provided by operating activities from continuing operations less capital expenditures for property and equipment which management believes is an important measurement of the Company's ability to generate additional cash from its business operations, and (ii) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted to exclude provision for income taxes, finance expenses, depreciation and amortization, share-based compensation, unrealized and realized (gain) loss on investments, (gain) loss from revaluation of contingent consideration, unrealized and realized foreign exchange (gain) loss, gain on fair value of derivative liabilities, impairment of property and equipment and right of use assets, gain on lease terminations, and certain other items, which management believes is not reflective of the ongoing operations and performance of the Company. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

The Company believes Adjusted EBITDA from continuing operations is a useful performance measure to assess the performance of the Company as it provides more meaningful ongoing operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance and other one-time or non-recurring expenses. The table below reconciles net loss to EBITDA from continuing operations and Adjusted EBITDA from continuing operations for the three and six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Net loss** | $**(48107)** | $**(6237)** | $**(60376)** | $**(21088)** |
| Loss (income) from discontinued operations | 41701 | (48) | 46305 | 5607 |
| Loss from continuing operations | (6406) | (6285) | (14071) | (15481) |
| *Add (deduct) the impact of:* |  |  |  |  |
| Provision for income taxes | 9598 | 9126 | 20105 | 16779 |
| Finance expenses | 8962 | 8745 | 17383 | 17140 |
| Amortization and depreciation | 3784 | 3780 | 7729 | 7576 |
| **EBITDA from continuing operations**<br> (a) | **15938** | **15366** | **31146** | **26014** |
| *Add (deduct) the impact of:* |  |  |  |  |
| Share-based compensation<br> (b) | 779 | 1960 | 2293 | 3445 |
| Unrealized and realized (gain) loss on investments<br> (c) | (7) | 227 | 735 | 227 |
| (Gain) Loss from revaluation of contingent consideration<br> (d) | (34) | 1827 | 346 | 3220 |
| Gain on fair value of derivative liabilities<br> (e) | (279) | (2922) | (376) | (1939) |
| Unrealized and realized foreign exchange (gain) loss<br> (f) | (648) | 104 | (607) | 389 |
| Impairment of property and equipment and right of use assets<br> (g) |  |  |  | 2438 |
| Gain on lease termination<br> (h) |  | (1169) |  | (1169) |
| Other one-time items<br> (i) | 267 | 1879 | 625 | 2665 |
| **Adjusted EBITDA from continuing operations** | $**16016** | $**17272** | $**34162** | $**35290** |

---

a) EBITDA from continuing operations is a non-GAAP measure and is calculated from net loss.

b) Represents non-cash share-based compensation expense.

c) Represents unrealized and realized loss on fair value changes investments.

d) Represents the revaluation of the Company's contingent consideration liabilities.

e) Represents the gain on fair value of conversion options.

f) Represents the remeasurement of USD denominated cash and other assets recorded in CAD functional currency.

g) Represents impairment charges taken on the Company's property and equipment and right of use assets.

h) Represents the gain taken as a result on lease termination.

------

i) Includes one-time fees incurred primarily in connection with the Company's acquisitions and other costs considered one-time in nature, such as expenses related to professional, consulting, legal, and accounting fees. These fees are not indicative of the Company's ongoing costs.

Adjusted EBITDA from continuing operations was relatively flat for the three and six months ended June 30, 2025 as compared to three and six months ended June 30, 2024.

The table below reconciles net cash provided by operating activities from continuing operations to free cash flow for the six months ended June 30, 2025 and 2024:

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30, 2025** | **June 30, 2024** |
|  | **(In thousands)** | **(In thousands)** |
| Net cash provided by operating activities - continuing operations | $**18479** | $**33316** |
| Capital expenditures for property and equipment | (4650) | (4094) |
| **Free Cash Flow** | $**13829** | $**29222** |

---

**<u>Critical Accounting Estimates and Policies</u>**

The Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. The Company bases its estimates on historical experience and assumptions on an ongoing basis. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and actual results, the Company's future financial statements will be affected.

There have been no significant changes to the critical accounting estimates from the information provided in Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*", as contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

**<u>Emerging Growth Company Status</u>** 

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's Consolidated Financial Statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

The Company will remain an emerging growth company until the earlier to occur of: (i) December 31, 2027 (a) in which the Company has total annual gross revenue of $1,235,000 or more, or (b) in which the Company is deemed to be a large accelerated filer, which means the market value of the Company's Common Shares that are held by non-affiliates exceeds $700,000 as of the last business day of the Company's most recent second fiscal quarter; and (ii) the date on which the Company has issued more than $1,000,000 in non-convertible debt during the prior three-year period.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

There have been no material changes in the Company's primary risk exposures or management of market risks from those disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

**Item 4. Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures**

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2025, the Company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and to provide reasonable assurance that such information is accumulated and

------

communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Limitations on Effectiveness of Controls and Procedures**

In designing and evaluating the Company's disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

In the ordinary course of business, the Company is involved in a number of lawsuits incidental to its business, including litigation related to intellectual property, employment, and commercial matters. Although it is difficult to predict the ultimate outcome of these matters, management believes that any ultimate liability would not have a material adverse effect on the Consolidated Balance Sheets or results of operations. As of June 30, 2025, there were no pending lawsuits that could reasonably be expected to have a material effect on the results of the Company's Consolidated Financial Statements.

**Item 1A. Risk Factors.**

Investing in the Company's Common Shares involves a high degree of risk. Please refer to Part I, Item 1A, "Risk Factors" in the Company's Annual Report for a description of the material risks and uncertainties to which the Company's business, financial condition and results of operations are subject. The Company may disclose changes to risk factors or disclose additional factors from time to time in its future filings with the SEC. Additional risks and uncertainties not presently known to the Company or that the Company currently deems immaterial may impair its business operations. There have been no material changes to the risk factors previously disclosed in Part I, Item 1A, "Risk Factors" in the Company's Annual Report.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

On August 20, 2024, the Board approved a share repurchase program to repurchase up to $10,000 of Common Shares. The share repurchase program authorizes the Company to repurchase up to 10,000,000 Common Shares of the Company at any time, or from time to time, from August 22, 2024 until August 21, 2025. The share repurchase program authorizes the Company to repurchase up to 65,361 Common Shares daily, which represents 25% of the Company's average daily trading volume on the TSX of 261,445 Common Shares. Any repurchases under the program may be made by means of open market transactions, negotiated block transactions, or otherwise, including pursuant to a repurchase plan administered in accordance with Rules 10b5-1 and 10b-18 under the Securities Exchange Act

------

of 1934, as amended. The size and timing of any repurchases will depend on price, market and business conditions, and other factors. During the second quarter of 2025, the Company repurchased Common Shares as set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Common Shares Purchased** | **Weighted Average Price Paid per Share** | **Total Number of Common Shares as Part of a Publicly Announced Program** | **Number of Common Shares that may yet be Purchased under the Program** |
| April 1 through April 30, 2025 |  | $— |  | 9255600 |
| May 1 through May 31, 2025 | 141000 | $0.38 | 141000 | 9114600 |
| June 1 through June 30, 2025 | 394000 | $0.26 | 394000 | 8720600 |
| For the Quarter Ended June 30, 2025 | 535000 | $0.29 | 535000 | 8720600 |

---

*ABI SF LLC Issuance* 

As previously disclosed, on January 23, 2020, the Company and certain consolidated entities acquired 49.9% of the outstanding equity interests in ABI SF, LLC. On January 19, 2024, the Company entered into an amendment to the original purchase agreement, pursuant to which the Company acquired the remaining 50.1% of outstanding equity interests in ABI SF, LLC. Pursuant to the amendment to the original purchase agreement, on June 2, 2025, the Company issued an aggregate of 2,119,451 common shares to the seller parties thereto at a price of $0.38 per share, which represents the twenty (20)-day volume-weighted average price of the Company's common shares on the OTCQX for the period ending on May 20, 2025, for a total approximate aggregate value of $805.

The securities described above were offered and sold in reliance upon (i) an exemption from registration provided by Section 4(a)(2) of the Securities Act, and (ii) exemptions from the formal valuation and minority shareholder approval requirements of MI 61–101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61–101 in respect of the Insider Participation as the fair market value (as determined under MI 61-101) of the Insider Participation in the Private Placement is below 25% of the Company's market capitalization (as determined in accordance with MI 61-101).

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5.** Other Information

*Unless otherwise noted, dollar amounts in this section are in thousands of U.S. dollars.*

<u>Disclosure in Lieu of Form 8-K Reporting</u>

On June 30, 2025, the Company filed a Current Report on Form 8-K (the "Original Form 8-K") disclosing, among other things, the approval by the Board of certain restructuring actions related to the Company's exit from the Michigan market, which is discussed under the caption "Recent Developments" in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q.

At the time of the filing of the Original Form 8-K, the Company was unable to make a good faith determination of an estimate or range of estimates required by paragraphs (b), (c) and (d) of Item 2.05 of Form 8-K with respect to the foregoing. The following disclosure amends, updates and restates the disclosure contained in Item 2.05 of the Original Form 8-K for the purpose of providing these estimates and serves as the required amendment to the Original Form 8-K.

------

***Under Items 2.05 Costs Associated with Exit or Disposal Activities.***

As previously disclosed, on June 27, 2025, the Board approved certain restructuring actions related to the Company's exit from the Michigan market, aimed at enabling the Company to focus on its operations in its more profitable markets. As part of the exit plan, the Company intends to sell of the Company's Michigan assets, including four cultivation and processing facilities, twenty retail dispensaries and real estate. The actions are expected to include an overall reduction of approximately 21% of the Company's workforce of approximately 1,200 as of June 30, 2025, with most of this reduction expected to occur by the end of the fourth quarter of fiscal year 2025. The Company expects the workforce reduction to comply with applicable laws. As a result, the Company estimates that it will incur approximately $1,050 to $1,200 in cash expenditures for employee transition, notice period and severance payments, and employee benefits.

The Company is currently engaged in an active program to sell the assets of TerrAscend MI, which is expected to be substantially completed in the second half of 2025. TerrAscend MI is presented as discontinued operations and has been excluded from continuing operations for all periods presented. As a result, the Company recognized a total impairment loss of $34,959 on certain buildings, equipment and leasehold improvements. Refer to Note 7 in the Consolidated Financial Statements for additional information.

Upon full implementation, the company expects the plan to result in reduced annual run-rate expenses by more than $200,000 by the end of its 2025 fiscal year. We may not be able to realize the cost savings and benefits initially anticipated, and costs may be greater than expected.

***Item 5.02 of Form 8-K. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.***

On August 6, 2025, the Board appointed Ziad Ghanem as Principal Financial Officer of the Company in addition to his current role as President and Chief Executive Officer, effective immediately.

------

**Item 6. Exhibits.** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit** |  | **Description of Exhibit Incorporated Herein by Reference** | **Description of Exhibit Incorporated Herein by Reference** | **Description of Exhibit Incorporated Herein by Reference** | **Description of Exhibit Incorporated Herein by Reference** | **Filed** |
| **Number** | **Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Herewith** |
| 3.1 | [<u>Articles of TerrAscend Corp., dated March 7, 2017.</u>](https://www.sec.gov/Archives/edgar/data/1778129/000110465921132465/tm2129883d1_ex3-1.htm) | 10-12G<br>| 000-56363 | 3.1 | 11/02/2021 |  |
| 3.2 | [<u>Articles of Amendment to the Articles of TerrAscend Corp., dated November 30, 2018.</u>](https://www.sec.gov/Archives/edgar/data/1778129/000110465921152682/tm2129883d2_ex3-2.htm) | 10-12G/A<br>| 000-56363 | 3.2 | 12/22/2021<br>|  |
| 3.3 | [<u>Articles of Amendment to the Articles of TerrAscend Corp., dated May 22, 2020.</u>](https://www.sec.gov/Archives/edgar/data/1778129/000110465921152682/tm2129883d2_ex3-3.htm) | 10-12G/A | 000-56363 | 3.3 | 12/22/2021<br>|  |
| 3.4 | [<u>By-laws of TerrAscend Corp., dated March 7, 2017.</u>](https://www.sec.gov/Archives/edgar/data/1778129/000110465921132465/tm2129883d1_ex3-3.htm) | 10-12G<br>| 000-56363 | 3.3 | 11/02/2021 |  |
| 31.1 | [<u>Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](tsndf-ex31_1.htm) |  |  |  |  | X |
| 31.2 | [<u>Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](tsndf-ex31_2.htm) |  |  |  |  | X |
| 32.1\* | [<u>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](tsndf-ex32_1.htm) |  |  |  |  | X |
| 32.2\* | [<u>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](tsndf-ex32_2.htm) |  |  |  |  | X |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |  |  |  |  | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |  |  |  |  | X |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |  |  |  |  | X |

---

------

\* This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TerrAscend Corp. under the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

# Certain information contained in this agreement has been omitted because it is not material and is the type that the registrant treats as private or confidential.

† Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TerrAscend Corp.** | **TerrAscend Corp.** |
| Date: August 7, 2025 | By: | /s/ Ziad Ghanem |
|  |  | **Ziad Ghanem** |
|  |  | **President and Chief Executive Officer**<br>**(*Principal Executive Officer and Principal Financial Officer)*** |

---

------

## Exhibit 31.1

------

**Exhibit 31.1**

**Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a)**

**as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Ziad Ghanem, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, of TerrAscend Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: August 7, 2025 |  |
|  | /s/ Ziad Ghanem |
|  | Ziad Ghanem |
|  | President and Chief Executive Officer |
|  | (Principal Executive Officer) |

---

------

## Exhibit 31.2

------

**Exhibit 31.2**

**Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a)**

**as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Ziad Ghanem, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, of TerrAscend Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| <br>Date: August 7, 2025 |  |
|  | /s/ Ziad Ghanem |
|  | Ziad Ghanem |
|  | President and Chief Executive Officer |
|  | (Principal Financial Officer) |

---

------

## Exhibit 32.1

------

**Exhibit 32.1**

**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Ziad Ghanem, President and Chief Executive Officer of TerrAscend Corp. (the "Company"), hereby certify, that, to the best of my knowledge:

1. the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| <br>Date: August 7, 2025<br>|  |
|  | /s/ Ziad Ghanem |
|  | Ziad Ghanem |
|  | President and Chief Executive Officer |
|  | (Principal Executive Officer) |

---

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TerrAscend Corp. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

------

## Exhibit 32.2

------

**Exhibit 32.2**

**Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Ziad Ghanem, President and Chief Executive Officer of TerrAscend Corp. (the "Company"), hereby certify, that, to the best of my knowledge:

1. the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| <br>Date: August 7, 2025<br>|  |
|  | /s/ Ziad Ghanem |
|  | Ziad Ghanem |
|  | President and Chief Executive Officer |
|  | (Principal Financial Officer) |

---

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TerrAscend Corp. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

------